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Abstract 
 
Hydroxyethyl starch (HES) 130/0.4 is an artificial colloid solution commonly used to treat shock in 
dogs. Adverse effects from this solution have been reported in people, including platelet 
dysfunction. It was unknown if HES 130/0.4 causes platelet dysfunction in dogs. Therefore, we 
investigated the in vitro and in vivo effects of HES 130/0.4 on platelet function in dogs. We used 
closure time (CT) using the platelet function analyser-100 and adenosine diphosphate-collagen 
cartridges as a platelet agonist, to measure platelet function in this report. In the in vitro study, two 
solutions were compared: HES 130/0.4 and HES 200/0.5. Citrated blood from ten healthy dogs was 
diluted 1:9 and 1:3 with HES 130/0.4, HES 200/0.5 and 0.9% sodium chloride (NaCl). Closure time of 
the diluted blood was measured. Only HES 200/0.5 increased the CT beyond the dilutional effect at 
the 1:3 dilution, to a median CT of 125 seconds (interquartile range, 117.5 to 139.5 seconds), 
suggesting that HES 200/0.5, but not HES 130/0.4, caused platelet dysfunction at this dilution. No 
effect of HES or dilution on CT was identified at the 1:9 dilution. In the in vivo study, haemorrhagic 
shock was induced by removing 48ml/kg of blood from eleven greyhounds under general 
anaesthesia. Dogs were randomised to receive either 20mL/kg of HES 130/0.4 or 80mL/kg of 0.9% 
NaCl intravenously over 20 minutes. Both the HES 130/0.4 and 0.9% NaCl group had a significantly 
increased mean CT after fluid administration to 91.4 seconds (95% CI 69.3-113.4) and 95.5 seconds 
(95% CI 78.2-112.8), respectively. The magnitude of change was significantly greater for the 0.9% 
NaCl group than the HES 130/0.4 group, indicating the increase in CT with HES 130/0.4 is most likely 
due to a dilutional effect. In this study we also investigated the effect of shock on platelet function 
by measuring CT before and after inducing haemorrhagic shock. We found haemorrhagic shock did 
not significantly change CT. This report suggests HES 130/0.4 does not cause significant platelet 
dysfunction in dogs. 
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1. Chapter 1: INTRODUCTION, OBJECTIVES AND HYPOTHESES 
1.1. Introduction 
The aim of this thesis was to investigate the effect of two commonly used hydroxyethyl starch 
solutions, HES 130/0.4 and HES 200/0.5, on canine platelet function. The first study compared the 
two solutions in vitro and the second study focused on the effect of HES 130/0.4 in vivo. The second 
study utilised a shock model, therefore, we also had to determine the effect of shock on platelet 
function. Our assessment of platelet function was based on closure time (CT), as measured by the 
Platelet Function Analyser 100 (PFA-100).  
 
1.2. Objectives 
1. To determine if HES 130/0.4 and HES 200/0.5 increases CT in vitro, beyond a dilutional effect 
(Chapter 3). 
2. To determine if haemorrhagic shock in anaesthetised dogs alters CT (Chapter 4). 
3. To determine if HES 130/0.4 increases CT, beyond any effect of shock or haemodilution 
(Chapter 4). 
 
1.3. Hypothesis 
We hypothesised that HES 130/0.4 would increase CT in vitro and in vivo, as measured by the PFA-
100. We also hypothesised that haemorrhagic shock in dogs would alter CT.  
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2. Chapter 2: LITERATURE REVIEW 
2.1. Platelet Function 
Haemostasis is a complex mechanism resulting in thrombus formation. Traditionally, haemostasis 
has been divided into separate stages, including primary haemostasis, secondary haemostasis and 
fibrinolysis. However, it has been found more recently to be a complex mechanism with all stages 
occurring synergistically, involving tissue factor bearing cells, platelets and the endothelium.1 The 
new theory is referred to as the cell-based model of coagulation. Endothelial injury is the most 
common initiator  of coagulation, caused by surgical incision or venepuncture, infectious disease 
processes, severe acidaemia, hypoxaemia, inflammation, hypotension and even during normal 
endothelial cell turn over.2  
The first step in forming a thrombus is the adhesion of platelets to the site of injury.3 Platelets are 
synthesised in bone marrow and smooth muscle cells, and, in small amounts, in the liver, spleen and 
kidneys.2 Its production is activated by thrombopoietin, which is produced in the liver and kidneys. 
The average lifespan of platelets in circulation in the dog is approximately 6 days.4 Platelets achieve 
primary haemostasis by forming a platelet plug in three interrelated steps. This includes adhesion of 
platelets to endothelial surfaces,5 activation of platelets, and platelet aggregation.6 The mechanism 
of platelet function can differ in high shear stress conditions within small and medium sized arteries 
compared to  low shear stress conditions within large arteries and in veins.5  
Endothelial injury initially exposes subendothelial collagen. As a result, platelets adhere to the 
extracellular matrix and surrounding endothelial cells, which is mediated by von Willebrand Factor 
(vWF), fibronectin, laminin and thrombospondin. Von Willebrand factor is an adhesive protein 
synthesised by platelet precursors, megakaryocytes. After synthesis, vWF is stored within alpha 
granules in platelets. In addition, they are also produced and stored in endothelial cells.7  Von 
Willebrand factor release is stimulated by thrombin, fibrin, vasopressin, collagen, platelet-activating 
factor, epinephrine or histamine.8 Once in circulation, it can bind to exposed collagen at the site of 
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endothelial injury. Platelets then adhere to the site of injury by binding to vWF, mediated by integrin 
αIIbβ3 receptors and glycoprotein (GP) Ibα, which is a component of the GP Ib-IX-V complex found on 
platelet surfaces.5 During high shear stress conditions, binding of vWF on collagen and loose binding 
of vWF to GP Ibα receptors result in platelet rolling along endothelial surfaces, facilitated by P-
selectin expression. During low shear stress conditions, fibronectin and laminin mediate adhesion. 
During the adhesion process, factor (F) VIII is released, and vWF forms a complex with FVIII to avoid 
rapid clearance from plasma.9 
Once platelets are adhered to the subendothelial collagen, they are further activated by agonists 
such as collagen, vWF,  thrombin, adenosine diphosphate (ADP), and thromboxane A2 (TXA2), as well 
as being activated by shear stress conditions.10 Activation causes degranulation of α granules and 
dense bodies, increased cytosolic calcium concentration, conformational change of platelets, release 
of ADP, serotonin and epinephrine, and activation of protein kinase C.6 Under high shear stress 
conditions, ADP is the primary promoter of platelet activation; while under low shear stress 
conditions, TXA2 promotes platelet activation.
11 Thrombin plays a key role as it activates platelets 
under all shear conditions via the protease-activated receptors (PAR)1 and PAR4, as well as the GP 
Ib-V-IX complex .5 Although activation of platelets usually follows adhesion, it can also occur 
independent of adhesion, for example when thrombin is generated during inflammation, which can 
promote pathologic thrombus formation.  
Platelet activation allows platelet aggregation to occur which leads to the formation of platelet 
plugs. Aggregation occurs by binding of platelet surface receptors, primarily integrin αIIbβ3 as well as 
GP Ib-IX-V, mediated by vWF, fibrinogen, thrombin, ADP and TXA2, in order to form a platelet plug.
6 
Thromboxane A2, produced by the arachidonic acid cascade in platelets, is one of the most 
important facilitators of aggregation by activating integrin αIIbβ3 receptors. In high shear stress 
conditions, vWF is the major ligand for platelet aggregation, while in low shear stress conditions 
fibrinogen is the major ligand.12 Once a platelet plug is formed, a cross-linked fibrin meshwork can 
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then be formed to stabilise the platelet plug. The fibrin meshwork has been historically described as 
secondary haemostasis.  
Concurrent to platelet plug formation, adjacent endothelium releases prostacyclin and nitrous oxide, 
which causes vasodilation and inhibits platelet aggregation. This prevents excessive thrombus 
formation.13   
 
2.2. Platelet Function Analysis 
There are several methods to assess platelet function in people and in dogs. Due to the complexity 
of primary haemostasis, and the importance of platelet interactions with cellular surfaces in vivo, no 
single platelet function test is without limitations. The different methods of platelet function analysis 
reviewed here are available for clinical and research use, and the understanding of the function and 
limitations of each test is important for interpretation of results. The PFA-100 is described in detail 
below, followed by other tests validated for use in veterinary medicine. 
2.2.1. Platelet Function Analyser - 100 
The PFA-100 is a point-of-care, bench top platelet analyser, which measures platelet function in high 
shear stress conditions in vitro.  A small volume of citrated whole blood (0.8 mL) is placed in a 
reservoir in a disposable test cartridge, which is then aspirated by a vacuum through a stainless steel 
capillary. This mimics the high shear stress conditions that platelets encounter in small and medium 
sized arteries. The sample reaches a small aperture (150 µm diameter) with a membrane coated 
with collagen, and either ADP or epinephrine, depending on the type of cartridge selected. The high 
shear stress conditions combined with the platelet agonists result in platelet adhesion, activation 
and aggregation followed by platelet plug formation, which occludes the small aperture. The time 
from the onset of aspiration to the time of aperture closure is measured in seconds, and is recorded 
as the closure time (CT).14  
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The validation of the PFA-100 in dogs is based on several studies.15-17 Reference intervals reported in 
these studies with the use of ADP and collagen cartridges were 53 – 98 seconds,15 47 - 81 seconds,16 
and 52 – 86 seconds.17 Reference intervals reported in these studies with the use of epinephrine and 
collagen cartridges were 92 - >300 seconds,15 67 – 210 seconds,16 and 97 - >300 seconds.17 Closure 
times with epinephrine and collagen activating cartridges resulted in greater variability in results,17 
making this cartridge less reliable in dogs. The variability is thought to be due to the lack of ability for 
epinephrine to induce significant platelet aggregation in dogs compared with people.18 
The PFA-100 has also been validated for use in greyhounds. This is important because greyhounds 
have different haematological reference intervals compared to non-greyhound breed dogs. A 
bleeding tendency during surgery has been reported in some greyhounds, which is thought to be 
due to increased fibrinolysis, although this mechanism is not completely understood. A study by 
Couto et al measured CT with ADP and collagen coated cartridges as well as epinephrine and 
collagen coated cartridges, which ranged from 63 to 92 seconds and 87 to 238 seconds 
respectively.19 Following this study, the same investigators measured CT in greyhounds with clinical 
postoperative haemorrhage, which found no significant difference in CT between greyhounds with 
clinical evidence of haemorrhage and those without noticeable haemorrhage, indicating normal 
platelet function in greyhounds with bleeding tendencies.20 
Several individual-related factors have shown to influence CT in dogs. Firstly a decrease in platelet 
count (< 100,000 platelets/µL17) can  increase CT, due to the decreased availability of platelets. A 
decrease in haematocrit, or packed cell volume (PCV) (< 2516 – 30%15,17) can also increase CT. A low 
haematocrit can affect platelet function due to changes in blood flow dynamics altering platelet 
interaction with the endothelium,21 which may also hold true for contact with the PFA-100 aperture. 
Another proposed reason is due to decreased ADP release as a result of fewer available red blood 
cells.22 Although a defined minimum PCV is difficult to specify, CT results should be interpreted in 
line with a concurrent PCV. Von Willebrand factor can also influence CT as it is essential in primary 
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haemostasis and platelet function.15,17 Therefore, the PFA-100 has the clinical utility to diagnose von 
Willebrand Disease (vWD) in dogs,17,23 and vWD should be considered if an increase in CT is detected 
in a clinical scenario.  
As described above, the PFA-100 has been used for the diagnosis of vWD, with improved sensitivity 
and specificity compared with the traditionally used buccal mucosal bleeding time,17 as well as 
contributing to the investigation of the mechanism of bleeding in greyhounds. It has also been used 
in dogs to monitor efficacy of aspirin therapy,15 Scott’s syndrome,24  as well as to assess the effect of 
HES solutions on platelet function.25,26 Unlike other platelet function tests such as flow cytometry, 
platelet aggregometry, and thromboelastography with platelet mapping, the PFA-100 has the added 
advantage of mimicking high shear stress conditions, which is more applicable to physiological 
conditions. However, as it is an in vitro test, it lacks platelet interaction with true endothelium and is 
limited by the lack of cellular release of factors and proteins which normally occurs during in vivo 
haemostasis. From our experience, although the use of this machine is technically simple, results can 
be variable at times, particularly if the CT is not measured immediately, venepuncture technique is 
poor, the sample is left to sit without adequate rocking, or the citrated blood sample is not kept at a 
standard temperature.  
There are limited studies on the use of the PFA-100 for detecting increased platelet reactivity or 
evaluating the risk of bleeding. One study in people found that CT was associated with increased 
perioperative red blood cell transfusion requirements in patients with aortic valve stenosis,27 
however there are no other studies which specifically address the association between CT and risk of 
haemorrhage. One study measured CT and platelet aggregometry immediately following trauma, 
which found increased platelet reactivity measured by aggregometry and this correlated with a 
decreased CT. Further studies are warranted to investigate the significance of a decreased CT and 
the use of CT to predict clinical bleeding.28 
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2.2.2. Other platelet function tests 
2.2.2.1. Buccal mucosal bleeding time 
Buccal mucosal bleeding time (BMBT) is a simple in vivo method for diagnosing primary haemostatic 
disorders, which can differentiate from secondary haemostatic disorders.29 A small incision is made 
on the mucosa of the upper lip with a standardized instrument, while the lip is being reflected 
dorsally with a gauze bandage tied over the muzzle. While gently removing blood from the mucosa 
with a filter paper, the time from when the incision is made until the time taken for bleeding to 
cease is measured in seconds.30 Two studies have reported normal BMBT in dogs with mean and 
standard deviations of 2.73 +/- 0.77 minutes (range 1.83 – 4.75 minutes),32 and 2.62 +/- 0.49 minutes 
(range 1.68 – 4.14 minutes).30 A prolonged BMBT was found in dogs with vWD, thrombocytopenia, 
thrombocytopathia, severe uraemia, and with aspirin therapy.30  Buccal mucosal bleeding time in 
greyhounds has also been reported with a mean reference interval of 2.15 minutes +/- 0.73 minutes 
(range 0.88 – 4.12 minutes), which is different to non-greyhound breeds.32 This study described one 
of the major limitations which are inter-observer and intra-observer variability which can both range 
up to approximately 2 minutes within the same dog. Another limitation of BMBT is that it does not 
predict surgical bleeding in dogs.30  
2.2.2.2. Platelet Aggregometry 
Platelet aggregometry is considered the gold standard method for detecting platelet dysfunction. 
There are two methods of platelet aggregometry, light transmission aggregometry using platelet rich 
plasma or electrical impedance aggregometry using whole blood, with both methods being validated 
for use in dogs.33-35 Platelet aggregometery measures platelet aggregation in response to various 
agonists added to platelet rich plasma or whole blood samples, depending on the method utilised. 
Platelet agonists that have been used include ADP, collagen, arachadonic acid, thombin and 
epinephrine.36 With light transmission aggregometry, the sample becomes more translucent over 
time as platelet aggregate, and therefore light transmission through the sample increases.33 Light 
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transmission is recorded graphically, which can evaluate the time to maximum aggregation and 
overall rate of aggregation.36 The more recently developed method of electrical impedance has the 
advantage of being able to use whole blood samples, which eliminates the process of producing 
platelet rich plasma for analysis. With this method platinum electrodes are placed in the whole 
blood sample, and the blood is gently stirred.34-35 Once the agonist is added, platelets form a 
monolayer over the electrodes, which impede electrical current between the two electrodes. The 
transmitted current is then traced into a graph similar to light transmission aggregometry.  
One of the major benefits of platelet aggregometry is its ability to quantitatively measure platelet 
function with the addition of varied platelet agonists. This technology has been used to measure 
platelet function in dogs after being given various therapies that may affect platelet function. 
Platelet aggregometry showed no significant change in platelet aggregation after HES 670/0.75 
administration to dogs, despite a significant decrease in platelet count.37 However it should be noted 
that the major limitation of this study is the small sample size. Various studies have also utilised this 
technology to investigate the effect of pimobendan,38 lipid emulsions,39 non-steroidal anti-
inflammatory drugs,40 aspirin,41  and clopidogrel on platelet function in dogs.41 Platelet aggregation 
has also been used to demonstrate decreased platelet function in dogs with infections,42 and 
increased platelet function in dogs with malignancies,43 which also demonstrates its benefits in being 
able to measure platelet hyper-reactivity. Experimentally, this technology has also been used to 
analyse platelet function in frozen canine platelet concentrates.44 In people this technology has been 
used for diagnosing vWD,45 although it has not been used in dogs for this purpose. Future scope for 
this technology for clinical use to diagnose primary haemostatic disorders, including vWD and to 
monitor drug therapy, are promising but its use is currently limited by availability. 
Limitations to light transmission platelet aggregometry include the requirements of sample 
preparation in order to produce platelet rich plasma. It can be time consuming and require 
expertise, the centrifugation process can activate platelets, and the temperature of blood and the 
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time elapsed between sample collection and processing can also affect results.46 Other limitations of 
aggregometry are that it does not mimic physiological conditions such as shear stress, and with light 
transmission aggregometry, the lack of red blood cells may also alter results.  
2.2.2.3. Flow cytometry 
Flow cytometry is a platelet function test validated for use in dogs,47,48 which has the ability to assess 
platelet membrane glycoproteins, ligands, and platelet derived microparticles in platelets before and 
after being stimulated by platelet agonists including ADP, collagen, thrombin and epinephrine.36 
Whole blood, platelet rich plasma or washed platelet samples can be used. Platelets are 
fluorescently labelled and light scatter is detected to quantify the type and number of receptors, and 
platelet surface antibodies expressed on platelet surfaces. One of the benefits of this platelet 
function test is that it can be used to investigate the mechanism of platelet dysfunction by labelling 
platelet receptors,49,50 and has been crucial in the development of our understanding of the 
mechanism of effects of different drugs on platelet function.51 In dogs, flow cytometry has been 
used to investigate the function of platelets during inflammation,52,53 and in dogs with immune 
mediated haemolytic anaemia.54,55 It has also been used to investigate the effect of different 
therapeutics, such as aspirin56 and cyclosporine,51 on platelet function. More recent investigations 
have used flow cytometry to assess the viability of platelets in canine platelet transfusion 
products.57,58 One of the major limitations of flow cytometry is that it is a bench top platelet function 
test limited to laboratory use, and in addition does not mimic in vivo platelet function under shear 
stress conditions.  
2.2.2.4. Thromboelastography 
Thromboelastography has been employed to assess hypercoagulability and hypocoagulability in 
dogs. However, thromboelastography alone is a global coagulation function test and, therefore, does 
not specifically assess platelet function. More recently however, thromboelastography with platelet 
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mapping has become available, which measures the influence of platelet function on 
thromboelastography.  
Thromboelastography involves adding a small amount of whole blood to a small cup with a pin 
suspended in the middle. Depending on the machine utilised, either the cup rotates 
(thromboelastography) or the pin rotates (thromboelastometry). As only thromboelastography has 
been used for platelet mapping, the following discussion will be based on thromboelastography 
alone.  With thromboelastography platelets can be activated by different activators, such as tissue 
factor, activator F, kaolin, arachidonic acid and ADP. Torque is created by rotation of the pin, which 
creates a graph reflecting generation of a clot.  Several measurements can be made from the graph 
including reaction time (R), which is the time to initiate fibrin formation; K-time (K), which is the time 
to form a clot strength of 20 mm; alpha-angle (α), which describes the speed of fibrin build up and 
cross-linkage; maximum amplitude (MA), which is the maximum clot strength; and clot lysis after 30 
minutes (LY30) and 60 minutes (LY60) after MA.  
Thromboelastography with platelet mapping requires three samples run concurrently. The first 
sample is citrated blood with kaolin activation (MAthrombin), which measures the maximum clot 
strength for global coagulation. The second sample is heparinised blood activated with activator F 
(MAfibrin), which isolates the fibrin contribution to the clot. The third sample is the MAfibrin sample 
with either ADP (MAADP) or arachidonic acid (MAAA) as an additional agonist. The formula (MAADP/AA – 
MAFibrin)/(MAThrombin – MAFibrin) x 100 is used to determine the platelet inhibition response. 
Thromboelastography with platelet mapping has shown to be associated with platelet aggregation in 
people.59 Thromboelastography has been used in dogs to assess the effect of clopidogrel41 and non-
steroidal anti-inflammatory drugs on platelet aggregation60 which also showed association with 
platelet aggregometry. Thromboelastography has also been utilised in the assessment for platelet 
function in dogs with hyperadrenocorticism.61 Thromboelastography has the advantage of being able 
to assess the global formation of a clot, including hypercoagulability and hypocoagulability, and now 
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with platelet mapping, includes specific assessment of platelet function. However one of the major 
disadvantages of thromboelastography with platelet mapping is the expense of requiring two 
thromboelastography machines to run concurrently, and currently there is minimal literature 
validating its use in dogs.   
2.2.2.5. Sonoclot 
Sonoclot is a global coagulation test that also has capability to measure platelet function. It has been 
validated for use in dogs40 and has been shown to be useful in monitoring unfractionated heparin 
doses in dogs.62 It has a probe with a sensor that detects torque as blood clots within a cuvette. The 
sensor detects the change in torque during clot formation which is displayed in a graph. The graph 
represents sonoclot activated clotting time (ACT), which is the time in seconds till change in torque is 
detected; clot rate, which is the rate of fibrin formation; and platelet function (PF), which is 
calculated by the software from the peak strength of the clot and the time to peak clot formation. 
Despite the name, PF, this calculated value also involves fibrin formation, therefore is not specific to 
platelet function alone. Compared to platelet aggregometry, this test is limited to thrombin-
stimulated platelet activation, therefore Sonoclot cannot be used to determine the effect of certain 
platelet inhibitors such as clopidogrel and aspirin.63  
2.2.2.6. Cone and plate(let) analyser 
The cone and plate(let) analyser is another bed-side platelet function test that uses whole blood in 
high shear stress conditions like the PFA-100, and has the advantage of being able to measure 
increase and decrease in platelet function. However this test in only validated for research use in 
people, and has not been validated for use in dogs.36  
2.2.3. Summary 
The role of platelet function in haemostasis is complicated by multiple factors contributing to its 
activation, adhesion to endothelium, and aggregation resulting in final clot formation. Therefore, 
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despite the multiple methods available in order to investigate platelet function, there is no single 
test which provides all the information required to assess platelet function. An ideal test would be 
readily accessible, easy to use with minimal inter-observer and intra-observer variability, have the 
ability to measure variable components of platelet function, and in addition, mimic physiological 
conditions. The PFA-100 fulfils some of these criteria as it is easy to perform, produces a 
measurement which is easily compared, has been validated for use in experimental research and is a 
bed-side test which mimics physiological shear stress conditions.  However using multiple methods 
of platelet function analysis would be able to provide more information on the mechanisms of 
platelet function. 
 
2.3. Hydroxyethyl Starch Solutions 
2.3.1. Properties of Hydroxyethyl Starch solutions 
Hydroxyethyl starch (HES) solutions are artificial colloid solutions that are used to treat shock by 
expanding blood volume. The colloid molecules are made by modification of natural polymers of 
amylopectin made from waxy maize starch.64 There are a variety of HES solutions available, which 
are characterised by their physical and chemical characteristics including mean molecular weight 
(MW), degree of substitution (MS), and hydroxyethylation ratio at carbon position C2 and C6 (C2/C6 
ratio). These properties influence the rate of degradation and separate the solutions into slowly 
degradable solutions such as HES 670/0.75, rapidly degradable solutions such as HES 130/0.4, or 
solutions having a medium rate of degradation such as HES 200/0.5. Slowly degradable products 
tend to have greater adverse effects. Other important properties include the carrier solution type in 
which the starch molecules are suspended in, such as 0.9% NaCl or a balanced crystalloid solution, 
and the concentration of starch molecules within the solution, most commonly 6% or 10%.64 These 
properties are discussed in more detail in this chapter. 
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The MW of HES solutions describe the mean MW of a polydispersed solution, meaning, there are a 
broad range of HES molecules with different MWs in one solution.64 The MW is often described as 
being high (> 400 kDa), medium (200 – 400 kDa), or low (< 200 kDa). The MW can influence the rate 
of degradation of HES solutions; with higher MW solutions having a slower rate of degradation, and 
lower MW solutions having a faster rate of degradation. The mean MW can be calculated by two 
different methods; the number average MW and the weight average (or mass average) MW.65 If 
there are larger molecules in a solution, the weight average MW is influenced to a greater degree 
than the number average MW. The ratio of weight average MW to the number average MW will give 
an index of the degree of polydispersity of the solution.65  
Lederer et al reported that previous methods of MW determination for currently labelled HES 
solutions are inaccurate.66 Using size exclusion chromatography coupled with low-angle laser light 
scattering techniques, HES labelled 450/0.7 was determined to have a MW of 670 KDa and HES 
200/0.5, a MW of 240 KDa.66 However HES 130/0.4 was found to have an accurate mean MW of 130 
KDa as determined by low angle laser light scattering technique.67 However, despite further accuracy 
on size, the in vitro molecular weight described by the manufacturer differs to the eventual in vivo 
MW. This is because when HES solutions are administered intravascularly, the small molecules (< 50 
kDa) are rapidly excreted by the kidneys.68 The larger molecules are hydrolysed by amylase into 
smaller molecules, as discussed in the pharmacokinetics chapter, resulting in an increase in the 
number of molecules in vivo. As a result the in vivo MW is lower than the in vitro MW.64 Metabolism 
of the molecules actually improves the colloid osmotic pressure, as it is the number of molecules, 
not absolute MW, that determines colloid osmotic pressure.  
The MS describes the average number of substitutions of hydroxyl groups with hydroxyethyl 
residuals at carbon position 2 (C2) and carbon position 6 (C6) on each glucose subunit within the 
hydroxyethyl starch polymer.64 Solutions can be highly substituted (0.62 – 0.75), have a medium 
substitution (0.5) or low substitution (0.4). The MS can be calculated by the formula, MS = W/(1-W) x 
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162/44; where W is the weight fraction of hydroxyethyl groups in the polymer, 162 is the mass of 
the starch, and 44 is the mass of the hydroxyethyl group.65 The MS determines the ability of amylase 
to cleave HES molecules in vivo into smaller molecules, resulting in a smaller in vivo MW.67 Higher 
MS solutions are more difficult to cleave by amylase, resulting in reduced enzymatic degradation and 
prolongation of intravascular retention.65  
The C2/C6 ratio is the ratio of hydroxyethylation at the C2 position compared to the C6 position. This 
property is also important as there is greater difficulty in cleaving HES molecules at C2 compared to 
C6. Hence, HES products with a higher C2/C6 ratio have a slower rate of degradation.69  
Another important characteristic of HES solutions is the solvent in which HES molecules are 
suspended in. Commonly used solvents include 0.9% NaCl or balanced crystalloid solutions. The 
characteristics of the solvents can influence acid-base and electrolyte balance. It has been shown 
that 0.9% NaCl as a solvent causes a significant decrease in blood pH, and an increase in chloride 
concentration and base deficit, compared to a balanced crystalloid solution.12 The concentration of 
hydroxyethyl starch molecules in the solvent is commonly 6% or 10%, depending on the product. 
The concentration of the solution affects the resulting plasma concentration,70 altering the rate of 
excretion and contributing to adverse effects, as well as the volume expansion effects.  
The two solutions most commonly used in people are 10% HES 200/0.5 and 6% HES 130/0.4. The use 
of high MW HES 670/0.75 has been associated with significant adverse effects and its use has fallen 
out of favour. Hydroxyethyl starch 200/0.5 has a medium mean MW of 200 kDa, a medium MS of 
0.5, and a C2/C6 ratio of 5:1, and is commonly described as a pentastarch solution. Due to these 
properties, HES 200/0.5 has a medium rate of degradation when compared to other HES solutions.70 
Hydroxyethyl starch 130/0.4 has a low mean MW of 130 kDa, a low MS of 0.4 and a high C2:C6 ratio, 
and is commonly described as a tetrastarch solution. Despite the high C2/C6 ratio, the low MW and 
MS have a greater influence on the behaviour of this solution, resulting in a rapid rate of 
degradation.65 The HES 130/0.4 solution under investigation described in this thesis has a 
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concentration of 6% suspended in a 0.9% NaCl solvent, although HES 130/0.4 in 10% solutions and 
balanced electrolyte solvents are also available.  
2.3.2.  Pharmacokinetics  
Once polydispersed HES solutions are administered intravenously, HES molecules with a MW lower 
than the renal threshold (40 - 60 KDa) are excreted by the kidneys.67,72 Larger molecules are cleaved 
by amylase, increasing the number of molecules contributing to colloid osmotic pressure.67,72 There 
is also a small increase in MS in vivo as the more highly substituted molecules resist cleavage. A 
small proportion of HES molecules are stored in the tissues and are excreted following 
redistribution.67  
Because 6% HES 130/0.4 has a low MW and low MS, it has the highest plasma clearance rate (31.4 
mL/min) and shorter half-life in people (12.1 hours), compared to the higher MW higher MS HES 
solutions, after a single dose administration of 500mLs.70 The maximum plasma concentration 
achieved was 3.7mg/mL. By 24 hours after administration, plasma concentrations decreased to less 
than 0.5 mg/ml. Compared to this, 6% HES 670/0.75 (which has a high MW of 670 KDa and a high MS 
of 0.75) and 10% HES 200/0.5 had a much slower rate of plasma clearance of 0.98 mL/min and 9.24 
mL/min respectively; a longer half-life of 46.4 hours and 30.6 hours respectively; and higher 
maximum plasma concentration of 13mg/mL and 8mg/mL respectively.67  
2.3.3. Pharmacodynamics  
The pharmacodynamic property of interest for HES solutions is the effect of these solutions on blood 
volume expansion. A study by Silverstein et al73 showed that administration of 20mL/kg of HES 
670/0.75 immediately increased blood volume by 40% and was able to maintain an increase of 30% 
for 240 minutes. In comparison, 80ml/kg of 0.9% NaCl was able to increase blood volume by 76%, 
however rapidly decreased to 20% blood volume expansion, despite the larger volume administered. 
This effect can be explained by Starling’s principle, which states that net fluid flow across a vessel 
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wall is dependent on the filtration coefficient, reflection coefficient, the balance between capillary 
and interstitial hydrostatic pressure and the balance between the capillary and interstitial colloid 
osmotic pressure. This can be described by the following equation: 
Jv = Kf[(Pc – Pi) – σ(πc –  πi)] 
where Jv is the net fluid flow across a vessel wall, Pc is the capillary hydrostatic pressure, Pi is the 
interstitial hydrostatic pressure, πc is the capillary oncotic pressure, πi is the interstitial oncotic 
pressure, Kf is the filtration coefficient, and σ is the reflection coefficient.
74,75 Therefore, 
administration of HES solutions, which have a higher MW and therefore higher oncotic pressure 
compared to crystalloid solutions, will result in increased intravascular oncotic pressure, resulting in 
prevention of extravasation of fluid, compared to a crystalloid solution.76-78 However it is also 
important to remember that artificial colloids such as HES will also cause an increase in hydrostatic 
pressure, resulting in some degree of extravasation of fluid into the interstitial space. The degree of 
extravasation of fluid, and hence an HES solution’s ability to expand blood volume, is also altered by 
patient factors such as albumin balance between the capillary and interstitium and capillary 
permeability, which can both be altered in diseased states.  
Although there are no studies on the pharmacodynamics of 6% HES 130/0.4 or 10% HES 200/0.5 in 
dogs, several studies have assessed the pharmacodynamics of these solutions in people. 
Administration of 500mL of HES 130/0.4 over 15 minutes resulted in a plasma volume increase of 
380mls over 4 to 6 hours, which returned to baseline within 8 to 24 hours. Despite the lower plasma 
concentration and shorter half-life of HES 130/0.4, there was no difference in plasma volume effect 
compared to 10% HES 200/0.5 or 6% HES 670/0.75.79,80  Also, there was no blood volume expansion 
effect 24 hours after a single dose despite the persistence of HES solution in plasma.79,81  
2.4. Indications for use of hydroxyethyl starch solutions 
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Hydroxyethyl starch solutions are used in the treatment of shock to rapidly increase and maintain 
intravascular blood volume. There are several advantages of artificial colloid solutions compared to 
crystalloid solutions. One advantage is that it can minimise development of interstitial oedema by 
maintaining colloid osmotic pressure.82,83 As less of the solution redistributes outside of the vascular 
space, it provides longer intravascular volume expansion effects compared with administration of 
crystalloid solutions,73 therefore requiring smaller volumes.84 Additional benefits may include the 
ability to reduce capillary permeability,85,86 and anti-inflammatory effects.87-89  
2.4.1 Use of hydroxyethyl starch solutions in the treatment of shock 
Shock can be defined as inadequate oxygen delivery (DO2) to tissues resulting in failure to meet 
oxygen demands, impairing oxidative metabolism.90 Failure of the cardiovascular system to deliver 
oxygen in order to meet oxygen demands is defined as circulatory shock.90 To maintain organ 
function, the cardiovascular system distributes oxygen to tissues to facilitate energy production, 
which is generated within mitochondria as adenosine triphosphate (ATP).91 Adenosine triphosphate 
is hydrolysed to ADP for normal cellular function. Adenosine triphosphate production also occurs 
during glycolysis, where 2 ATP are produced per glucose molecule, an anaerobic process. When 
there is adequate oxygen available, pyruvate, which is an end product of glycolysis, enters the Kreb’s 
cycle resulting in oxidative phosphorylation and production of an additional 36 ATP per glucose 
molecule. During shock, aerobic metabolism can no longer occur and pyruvate converts to lactate 
instead of entering the Kreb’s cycle. This produces nicotinamide adenine dinucleotide, a reducing 
substrate, which is used to feed back into glycolysis and continue the small production of 2 ATP per 
glucose molecule. This eventually results in inadequate energy production for cellular function 
resulting in cellular and organ dysfunction.  
The primary indication for the use of HES solutions is for rapid blood volume expansion in patients 
with circulatory shock. Some clinicians prefer using HES solutions for fluid resuscitation instead of 
crystalloid solutions, as colloid solutions have the benefit of maintaining a longer blood volume 
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expansion effect following administration.73 Although natural colloids, such as human albumin, are 
preferable in people due to potential risks associated with HES solutions, HES solutions are still 
widely utilised in dogs due to the limited availability of canine albumin, the risks of human albumin 
use in dogs, in addition to the costs associated with natural products.92 There is also some risk to 
rapidly infusing any natural product due to potential immunological incompatibility.  
Silverstein et al demonstrated that the blood volume expansion effects of 80mL/kg of crystalloid 
solution was no different to 20mL/kg of an artificial colloid solution.73 Four dogs weighing 20kg were 
administered different resuscitative fluids one week apart, including an isotonic crystalloid solution 
of 0.9% NaCl, a hypertonic crystalloid solution of 7.5% NaCl, and two artificial colloid solutions 
Dextran-70 and 6% HES 670/0.75, as well as a control group of no resuscitative fluid administration. 
In-line haematocrit monitoring was used to determine real-time changes in blood volume during and 
after fluid administration for up to 240 minutes. For each fluid type, the degree of blood volume 
expansion was related to the volume of fluid administered. Immediately after the completion of 
crystalloid administration, the peak blood volume rapidly declined, while immediately after colloid 
administration the blood volume continued to increase, indicating intravascular fluid shift from 
other compartments. The cumulative blood volume expansion was greatest with colloids. However, 
this study did not specifically investigate more modern HES solutions, 6% HES 130/0.4 or 10% HES 
200/0.5. 
Gandhi et al compared volume efficacy of 6% HES 130/0.4 with 6% HES 670/0.75 in a controlled 
double blinded multicentre trial in people.81 Efficacy of HES solutions was measured by the volume 
required for intraoperative volume replacement, as guided by central venous pressure and arterial 
blood pressure. They found that the volume required for intraoperative volume replacement was 
not significantly different between the two solutions. Gallandat et al compared volume efficacy 
between 6% HES 130/0.4 and 10% HES 200/0.5 in a prospective randomised double-blinded 
multicentre study in people.93 Fifty nine people undergoing coronary artery bypass grafting were 
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enrolled in the study. The efficacy as a volume expander was measured by the required volumes of 
fluid, hemodynamic parameters (heart rate, mean arterial pressure, central venous pressure, 
pulmonary capillary wedge pressure, cardiac index), and colloid osmotic pressure. These values were 
not significantly different, suggesting 6% HES 130/0.4 and 10% HES 200/0.5 have similar volume 
replacement/expansion properties to each other. It is likely that the reason for these similarities in 
volume expansion is the similar number of HES molecules in vivo, which determine the colloid 
osmotic pressure, not the size of the molecules. A recent study by Barros et al compared the effect 
of a 1:1 volume replacement dose of 6% HES 130/0.4 to 3:1 volume replacement dose of lactated 
Ringers solution (LRS) administered to splenectomised dogs with haemorrhagic shock. Six percent 
HES 130/0.4 provided greater blood volume expansion effect compared to LRS, 45 minutes and 90 
minutes after administration. This study also measured oxygen extraction ratio (O2ER), which is an 
objective measure of shock. Haemorrhagic shock increased O2ER significantly from base line, and 
both solutions decreased O2ER back to base line 5 minutes after fluid administration. However, 45 
minutes after administration of LRS, the O2ER increased significantly from base line values, while 
O2ER remained the same 45 minutes after 6% HES 130/0.4 administration.  This study suggests that 
one third of a dose of 6% HES 130/0.4 compared to LRS is superior for the treatment of 
haemorrhagic shock in splenectomised dogs.  
2.4.2. Other indications for the use of hydroxyethyl starch solutions 
Hydroxyethyl starch solutions are also used as a continuous infusion to maintain colloid osmotic 
pressure in dogs with hypoalbuminaemia.15,16 Hypoalbuminaemia results in a decrease in colloid 
osmotic pressure,82 as albumin accounts for the majority of the plasma colloid osmotic pressure in a 
non-linear relationship.94,95  It has been shown by Smiley and Garvey,83 that the administration of 6% 
HES 670/0.75 (dose ranging from 9 to 27mL/kg), was associated with a subjective improvement in 
clinical signs of peripheral oedema in 18 of 26 dogs, and resulted in a significant increase in colloid 
osmotic pressure in all 13 dogs in which colloid osmotic pressure was measured. However this study 
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did not have a control population, therefore improvement in peripheral oedema and colloid osmotic 
pressure may have occurred with administration of a crystalloid solution or no solution at all. 
Another study by Moore and Garvey82 found 6% HES 670/0.75 improved colloid osmotic pressure 
immediately after administration of a single dose, but decreased back to base line 12 hours after 
administration in dogs with hypoalbuminaemia.  
In people, there was no difference in colloid osmotic pressure after 6% HES 200/0.5 or 6% HES 
130/0.4 administration.67,93 Currently, there are no studies which determine the colloid osmotic 
pressures in dogs after administration of 6% HES 130/0.4 or 10% HES 200/0.5 as a bolus or as a 
continuous rate infusion. 
Another interesting finding specific to 6% HES 130/0.4 is its potential anti-inflammatory effects and 
capability of decreasing capillary permeability. Recent experimental studies on septic animal models 
have shown that HES solutions, compared with crystalloid and gelatine-based colloid solutions, can 
decrease capillary permeability,85,86 down regulate the expression of adhesion molecules, inhibit 
neutrophil recruitment, and decrease cytokine production.87-89,96,97 In particular, 6% HES 130/0.4 has 
been shown to be superior to 10% HES 200/0.5 in regards to these effects.85 Research in this area is 
still in its early phases, and recommendations for the use of 6% HES 130/0.4 specifically to decrease 
capillary permeability and inflammation cannot be recommended.  
 
2.5. Adverse Effects of hydroxyethyl starch solutions 
2.5.1. Introduction 
Despite the many advantages of HES solutions, the use of HES solutions is controversial due to an 
association with adverse effects.98-100 One of the major adverse effects is the risk of blood loss and 
increased transfusion requirements, mainly due to development of platelet dysfunction. In addition, 
there is evidence for risk of developing acute kidney injury (AKI) in people with sepsis.101 Other rare 
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complications include allergic reactions, development of pruritus, as well as metabolic acidosis, 
depending on the carrier solution.100 Due to these adverse effects that HES solutions can cause, and 
with the additional costs of these solutions compared with use of crystalloid solutions, a complex 
and ongoing debate is continuing in the human medical literature.  
2.5.2. Platelet dysfunction 
It is well documented that HES solutions can cause both human50,102-105 and canine25,26,37 platelet 
dysfunction.  Proposed mechanisms include binding of vWF,28,29 HES molecules coating platelet 
surfaces, blocking access to platelet surface protein integrin αIIbβ3, preventing platelet adhesion and 
aggregation.108  
2.5.2.1. Platelet dysfunction in people 
Stogermuller et al found that 10% HES 200/0.5 decreased expression of integrin αIIbβ3, in vitro and in 
vivo in healthy volunteers, but not P-selectin or glycoprotein Ib receptor expression.109 Franz et al 
used platelet flow cytometry to examine the effect of various HES solutions (HES 130/0.4, 200/0.6, 
70/0.5 and 400/0.8) on agonist induced activation of integrin αIIbβ3 complex and P-selectin, in 
healthy volunteers.49 There was decreased expression of integrin αIIbβ3 receptors, but not P-selectin, 
with all but 6% HES 130/0.4 administration. These findings suggest that HES molecules may cause 
platelet dysfunction by decreasing the availability of functional receptors required for normal 
adhesion and aggregation. Interestingly, although a variety of HES solutions affected integrin αIIbβ3 
receptor expression in this study, 6% HES 130/0.4 did not, suggesting it may be a superior solution to 
other HES solutions if platelet dysfunction was of concern.  
Another proposed mechanism is a non-specific binding of HES molecules to platelet surfaces. Deusch 
et al found using flow cytometry that HES molecules with fluorescent labelling were found to coat 
platelet surfaces independent of integrin αIIbβ3 binding.
108 Although the exact mechanism is 
unknown, this mechanism of platelet dysfunction is often described as platelet coating. Although 
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impaired intracellular calcium signalling due to HES administration was previously thought to 
contribute to platelet dysfunction, this has been more recently disproven.110  
2.5.2.2. Platelet dysfunction in dogs 
There are four studies concerning the association of HES solutions with platelet dysfunction in dogs. 
Two published studies assessed the effect of 6% HES 670/0.75 on canine platelet function using the 
PFA-100, in vitro and in vivo.25,26 Canine blood diluted at a ratio of 1:3 with 6% HES 670/0.75 in vitro 
increased CT,26 and a 20 mL/kg dose of 6% HES 670/0.75 administered to healthy dogs in vivo also 
increased CT.25,26 Both of these studies support that 6% HES 670/0.75 causes canine platelet 
dysfunction, although the effect of dilution alone on CT in the second study was not specifically 
addressed. One other study assessed the effect of 10mL/kg of 6% HES 670/0.75 on platelet function 
in anaesthetised dogs, using platelet aggregometry, and found no difference in platelet aggregation 
compared to administration of 10ml/kg of LRS.37  
More recently, 6% HES 130/0.42 was compared with saline solution in vitro.111 This particular 
solution is a low MW, low MS HES solution with a slightly higher MS than 6% HES 130/0.4, and 
derived from potato starch instead of maize. This study found that platelet dysfunction occurred 
with 6% HES 130/0.42 at a 1:3 dilution with blood as measured by the PFA-100. A direct comparison 
of all fluid solutions would be ideal, however this is difficult due to different availability of products 
in different countries. In addition, in vivo studies are warranted for further investigation of 6% HES 
130/0.42 on platelet function in dogs. 
No studies have investigated the effect of 6% HES 130/0.4 and 10% HES 200/0.5 specifically on 
canine platelet function. 
2.5.3.  Effect on von Willebrand Factor and Factor VIII 
In people HES solutions cause a decrease in circulating vWF and FVIII in healthy volunteers and 
clinical patients.67,106,107,112 Although dilution alone can cause a decrease in any factor 
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concentration,113 the decrease in vWF and FVIII was found to be beyond a dilutional effect.106,107 The 
cause of this dilution-independent decrease in vWF is unclear; some authors have suggested that it 
may be due to binding of vWF to HES molecules, resulting in increased clearance of vWF.71,114 The 
decrease in FVIII is likely due to the decrease in vWF, which is a carrier protein for FVIII. Decrease in 
vWF and FVIII results in impaired ristocetin cofactor activity and prolongation of activated partial 
thromboplastin time.112 Increase in CT, as measured by the PFA-100, has been attributed to a 
decrease in vWF in people115 and in dogs.23  
Despite these earlier findings with the use of slowly degradable HES solutions in people, 6% HES 
130/0.4 was found not to decrease vWF or FVIII in clinical patients.93,116 One limited study in 
anesthetised dogs found that 10ml/kg administration of 6% HES 130/0.4 resulted in no significant 
change in FVIII or vWF, although this finding may be due to the low dose administered.37  
2.5.4. Fibrin formation and fibrinolysis 
Hydroxyethyl starch solutions were found to impair thrombin-fibrinogen interactions and fibrin clot 
formation.117,118 The effect of HES solutions on fibrinolysis is controversial. Some studies showed 
increased fibrinolysis in vitro119 and in vivo,120  while others found no effect.112 A recent study 
showed that 6% HES 130/0.4, when added to canine blood in vitro, resulted in hypocoagulable 
parameters on TEG consistent with dose-dependent alteration in fibrinogen concentration and 
inhibition of platelet function.121 Further studies are warranted to investigate the effect of 6% HES 
130/0.4 on fibrinolysis.  
2.5.5.  Acute kidney Injury 
Hydroxyethyl starch solutions, including HES 130/0.4, are known to cause acute kidney injury (AKI) in 
people. There are very few studies which have investigated the exact mechanism of AKI secondary 
to HES 130/0.4 administration.122-124 One of the most commonly suggested mechanisms is the 
development of osmotic nephrosis-like lesions, which includes proximal tubular cell swelling and 
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vacuolisation, due to accumulation of proximal tubular vacuoles via pinocytosis. This was 
demonstrated in a septic rat model where renal histopathology was compared after HES 130/0.4, 
gelatine or 0.9% NaCl administration.122 This study found that septic rats which received HES 130/0.4 
had greater dilation of peritubular capillaries, increased renal tubular cell death (verified by cell 
swelling and fragmentation of cell nuclei), and large numbers of vesicles within the proximal tubular 
epithelial cells, compared to rats which received 0.9% NaCl. This study also demonstrated increased 
neutrophil gelatinase-associated lipocalin, which is an early marker of kidney injury in rats which 
received HES 130/0.4 compared with 0.9% NaCl. This same group of investigators also performed an 
in vitro study where different concentrations of HES 130/0.4 were applied to harvested proximal 
tubular cells and incubated over 21 hours.123 Hydroxyethyl starch 130/0.4 caused tubular cell injury 
in a dose dependent manner, when compared to 0.9% NaCl, and fluorescent images revealed small 
vesicular-like structures and large agglomerates which was similar to the earlier study’s histological 
findings. Contrary to these findings, however, a similar in vitro model demonstrated that HES 
blunted the damage induced by incubation with tumour necrosis factor α.124  
A porcine study with histologic examination of kidneys after HES 130/0.42 administration also 
showed tubular epithelial cell vacuolisation suggestive of osmotic nephrosis-like lesions.125 This study 
also demonstrated significantly increased macrophage infiltration and tubular damage with HES 
200/0.5, but not HES 130/0.4, when compared to the control solution of lactated Ringer’s. These 
results may indicate some advantages of using a lower MW and MS solution. In an ovine 
endotoxaemic shock model, intraluminal protein precipitates and cellular injury was present after 
HES 200/0.5, HES 130/0.4 and 0.9% NaCl administration, however was significantly greater with HES 
200/0.5 administration, also supporting the advantages of lower MW and MS solutions.126  
The only in vivo study in people which investigated the mechanism of AKI with HES administration 
found that after administration of HES to brain-dead kidney donors, histopathology demonstrated 
osmotic-nephrosis-like lesions in the tubules.127 However only three kidneys were examined, and the 
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type of HES solution was not specified. Therefore, although it is known that HES solutions can cause 
kidney injury in people, there is limited understanding of the mechanism of this process. There are 
currently no studies which demonstrate kidney injury in dogs, therefore, although precautions 
should be taken given the current literature, it is unknown if kidney injury occurs in dogs with HES 
administration.  
2.6. Clinical use of hydroxyethyl starch 130/0.4 
The use of HES 130/0.4 has become controversial in people due to adverse effects described in the 
earlier chapters. In 2013, HES 130/0.4 was taken off the market in the United Kingdom by the 
Medicines and Healthcare Products Regulatory Agency, and the United States Food and Drug 
Administration has recommended against its use in critically ill patients or those with pre-existing 
renal dysfunction. In addition, the most recent 2012 Surviving Sepsis Campaign Guidelines 
recommends ‘against the use of HES for fluid resuscitation of severe sepsis and septic shock’.128  
These changes in guidelines have evolved from four studies.101,129-131 The first of these, the Efficacy of 
Volume Substitution and Insulin Therapy in Severe Sepsis (VISEP) trial, was a multicentre randomised 
study comparing 10% HES 200/0.5 with a balanced crystalloid solution, Ringers lactate. This study 
was also investigating insulin therapy in severe sepsis, and was terminated early due to 
hypoglycaemia in patients with strict insulin control. The results therefore included 537 patients 
with severe sepsis in a multidisciplinary intensive care unit. They found that administration of HES 
200/0.5 resulted in a less positive fluid balance, greater increase in central venous pressure (CVP) 
and central venous oxygen saturation; however the multivariate analysis found HES 200/0.5 was an 
independent predictor for renal replacement therapy requirement and 90 day mortality in a dose 
dependent manner.130 However, these results are not directly applicable to HES 130/0.4 due to 
difference in concentration, MW and MS. 
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Following this, The Scandinavian Starch for Severe Sepsis/Septic Shock (6S) trial was published, 
which was a multicentre blinded trial, including 798 patients with septic shock randomised to receive 
HES 130/0.42 in a balanced solution or Ringer’s acetate for blood volume expansion within the first 3 
days of the trial.129 Thereafter, both groups received open-labelled HES 130/0.42 and or Ringer’s 
acetate at the attending clinician’s discretion. The HES 130/0.42 group was associated with greater 
90 mortality rates, a greater number of patients dependent on renal replacement therapy, and 
significantly more transfusions.  
The largest study, The Crystalloid versus Hydroxyethyl Starch Trial (CHEST),132 included 7000 medical 
and surgical ICU human patients randomised to receive fluid resuscitation with either HES 130/0.4 or 
0.9% NaCl. The median dose of HES 130/0.4 administered was 5ml/kg/day for 4 days. This study, as 
with the VISEP study, found a greater increase in CVP and lower positive fluid balance in the HES 
130/0.4 group. However, this group received greater volumes of blood products, had a greater need 
of renal replacement therapy, and had greater adverse effects, mostly pruritus. This study however 
did not show a difference in mortality, possibly because people who were unlikely to survive were 
excluded, and the mortality was less than the calculated power required to find significant difference 
between the two groups. It should be noted as well that this study included a general intensive care 
unit population, not a septic population like the other studies. 
The CRYSTMAS study randomised 174 people with severe sepsis to receive either HES 130/0.4 or 
0.9% NaCl for fluid resuscitation.131 The mean volume of HES 130/0.4 administered was 1379mls 
over a four day period. There was no difference in blood volume expansion, need for renal 
replacement therapy or mortality in this study. The lack of significant difference may be due to the 
low numbers of people enrolled, and hence lack of power to detect significant difference. Despite 
these results, there was no benefit in the use of HES 130/0.4 and with the additional costs of this 
product compared with a crystalloid solution its use was not supported by the results of this study. 
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Although several meta-analyses have also supported these findings of greater transfusion 
requirements, increased risk of acute kidney injury and increased risk of mortality with low MW and 
MS HES solutions,133-134 there are limited studies investigating the safety of these products in other 
patient populations such as hypovolaemic shock, trauma or perioperative patients.134 The only study 
specifically investigating people sustaining trauma is by James et al, in which 115 people with severe 
blunt or penetrating trauma were randomised to receive HES 130/0.4 or 0.9% NaCl for fluid 
resuscitation.135 In people with penetrating trauma, the volume administered was less, lactate 
clearance was faster, and there was a lower incidence of kidney injury with HES 130/0.4 
administration. In the blunt trauma group, there were greater transfusion requirements in the HES 
130/0.4 group, however, the HES 130/0.4 group also had higher trauma scores. This study was 
discontinued early due to slow recruitment of cases and did not measure mortality as a primary end 
point.     
The major concern for the use of HES 130/0.4 in the perioperative period is the risk of inducing 
coagulopathy and higher transfusion requirement. There are minimal studies investigating the effect 
of HES solutions in the perioperative and postoperative period. A pooled analysis of randomised 
clinical trials including people undergoing orthopaedic, cardiac and urologic surgery compared the 
effect of HES 130/0.4 and HES 200/0.5 on coagulation parameters, blood loss and transfusion 
requirements.136 Two hundred and twenty eight people were included in the HES 130/0.4 group and 
221 people were included in the HES 200/0.5 group. This study found a greater prolongation in 
activated partial thromboplastin time, lower vWF concentration, lower platelet count, and greater 
blood loss and transfusion requirements in the HES 200/0.5 group, despite the HES 200/0.5 receiving 
a lower volume of the study fluid. This study suggests that there is less risk of haemorrhage with the 
use of HES 130/0.4 compared with HES 200/0.5, however, this study did not compare the effect to 
crystalloid solutions. A meta-analysis of randomised trials compared the risk of postoperative 
bleeding between use of HES 130/0.4 with albumin administration in people undergoing 
cardiopulmonary bypass. This study included 18 trials with 970 people. They found that HES 130/0.4 
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increased the risk of postoperative blood loss by 33.3%, and also resulted in a significantly greater 
number of re-operations and increased transfusion requirements; however there was no difference 
in mortality between the two groups.  
Although there are some advantages in using HES 130/0.4 for blood volume expansion, the adverse 
effects such as AKI, haemorrhage and increased transfusion requirements should be considered. 
Despite the significant amount of literature in people describing these adverse effects, the exact 
mechanism causing these adverse effects are still under investigation. Currently there is minimal 
evidence for or against the use of HES 130/0.4 in dogs, although it should be used with caution. 
Further knowledge is required to determine if these adverse effects occur in dogs and if they are 
clinically relevant, in addition to a better understanding of the mechanisms contributing to these 
adverse effects.    
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3. Chapter 3: EFFECT OF HYDROXYETHYL STARCH 130/0.4 AND 200/0.5 SOLUTIONS ON CANINE 
PLATELET FUNCTION IN VITRO  
 
3.1.    Abstract 
Objective - To determine whether dilution of blood samples from healthy dogs with 2 hydroxyethyl 
starch (HES) solutions, HES 130/0.4 and HES 200/0.5, would result in platelet dysfunction as  
Measured by closure time (Ct) beyond a dilutional effect. 
Sample - Citrated blood samples from 10 healthy dogs with a Ct within reference limits (52 to 86 
seconds). 
Procedures - Blood samples were diluted 1:9 and 1:3 with 6% HES 130/0.4 and 10% HES 200/0.5 
solutions and saline (0.9% NaCl) solution. Dilutions at 1:9 and 1:3 mimicked 10 mL/kg and 30 mL/kg 
doses, respectively, ignoring in vivo redistribution. Closure time was measured with a platelet 
function analyzer and compared among dilutions. 
Results - A dilutional effect on Ct was evident for the 1:3 dilution, compared with the 1:9 dilution, 
but only HES 200/0.5 increased the Ct beyond the dilutional effect at the 1:3 dilution, to a median Ct 
of 125 seconds (interquartile range, 117.5 to 139.5 seconds). No effect of HES or dilution on Ct was 
identified at the 1:9 dilution. 
Conclusions and Clinical Relevance - 1:3 dilution of blood samples from healthy dogs with HES 
200/0.5 but not HES 130/0.4 significantly increased Ct beyond the dilutional effect, suggesting that 
IV administration of HES 200/0.5 in dogs might cause platelet dysfunction. 
 
3.2. Introduction 
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Hydroxyethyl starch solutions are artificial colloid solutions used in dogs to treat shock by expanding 
blood volume. The use of HES is controversial because of its association with platelet dysfunction in 
people1–5 and dogs,6–8 and in human medicine, its use has been associated with an increase in 
intraoperative blood loss and transfusion requirements.1,9–12 This effect is particularly relevant to 
solutions with a high molecular weight and molar substitution,1,9,10 such as the commonly used 
solution HES 670/0.75, which has a high molecular weight of 670 kDa and a high molar substitution 
of 0.75. A platelet function analyzer can be used to assess platelet function in high shear stress 
conditions.13 The device measures closure time (Ct), which is the time taken in seconds for a small 
aperture, coated with a platelet agonist, to be closed by platelet plug formation.13 An increase in Ct 
beyond the reference interval of 52 to 86 seconds,14  through use of cartridges coated with collagen 
and ADP as a platelet agonist, indicates platelet dysfunction in dogs. Dilution of blood that results in 
a decrease in Hct or PCV (< 25%15 to 30%14,16) and platelet count (< 100 x 109 cells/L14) can also 
increase Ct. Two studies6,7 assessed the effect of HES 670/0.75 on canine platelet function by use of 
the PFA-100. Canine blood samples diluted at a ratio of 1:3 with HES 670/0.75 solution led to an 
increase in Ct,6 and HES 670/0.75 administered IV to healthy dogs at a dose of 20 mL/kg also 
resulted in an increase in Ct.6,7 The findings of both studies support the hypothesis that use of HES 
670/0.75 can cause platelet dysfunction in dogs, although the effect of dilution alone on Ct in the 
second study was not specifically addressed. In another study8 in which HES 670/0.75 was 
administered to anesthetized dogs at a dose of 10 mL/kg IV, platelet aggregometry revealed no 
difference in platelet function, compared with platelet function after administration of lactated 
Ringer’s solution. Because of the complications associated with the use of HES 670/0.75 in people, 
HES solutions with lower molecular weights and molar substitutions, such as HES 130/0.4 and HES 
200/0.5, were developed to minimize adverse effects, such as platelet dysfunction. Evidence for a 
difference between these 2 HES solutions, however, is mixed in regard to their effect on platelet 
function in people. Whereas some studies2,17,18 have indicated that administration of HES 130/0.4 
does not cause platelet dysfunction, others have shown that use of HES 130/0.4 causes platelet 
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dysfunction to the same4 or lesser5 degree than that caused by HES 200/0.5. No consensus has been 
reached on the clinical implication of using an HES solution of lower molecular weight and molar 
substitution. Although a study19 has shown some differences in blood loss and transfusion 
requirements among people treated with HES solutions of different molecular weights and molar 
substitutions, several meta-analyses have failed to show a significant difference.1,20,21 
Little research has been conducted to investigate the effect of HES solutions of low molecular weight 
and molar substitution on platelet function in dogs. One study22 revealed that dilution of canine 
blood samples with HES 130/0.42 at a ratio of 1:3 resulted in an increase in Ct beyond a dilutional 
effect.22 The product HES 130/0.4, which has a low molecular weight and molar substitution and is 
commercially available in North America and Australia, has different properties from HES 130/0.42. 
The product HES 200/0.5 is also available in Australia. Whether use of HES 130/0.4 causes platelet 
dysfunction in dogs is unknown, as is whether use of HES 200/0.5 would cause worse platelet 
dysfunction because of its higher molecular weight and molar substitution than HES 130/0.4. The 
purpose of the study reported here was to measure Ct in samples of canine whole blood diluted with 
HES 130/0.4 and HES 200/0.5 in vitro and to compare the results with those of whole blood diluted 
with saline (0.9% NaCl) solution. We hypothesized that dilution alone would result in a dilution-
dependent increase in the Ct and that whole blood samples diluted with HES 200/0.5 would have a 
longer Ct than those diluted with HES 130/0.4, beyond any dilutional effect. 
 
3.3 Material and methods 
Animals—Ten healthy adult dogs (6 males and 4 females) owned by hospital staff members were 
included in the study after owner consent was obtained. The median age of the dogs was 4 years 
(IQR, 2 to 8 years), and the median body weight was 28.2 kg (IQR, 16.2 to 31.2 kg). All dogs were 
considered healthy on the basis of the absence of the following factors: disease or illness within 1 
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month prior to study inclusion; history of coagulopathy or disease that may affect hemostasis; 
treatment with NSAIDs, propofol, synthetic colloids, or antimicrobials within 1 month prior to study 
inclusion; and abnormal findings during physical examination. Each dog had a PCV > 40%; platelet 
count > 200 X 109 cells/L as measured with a hematologic analyzera and verified by manual count; 
mean Ct within the reference interval of 52 to 86 seconds,14 as measured in duplicate with the 
platelet function analyzera by use of cartridges coated with collagen and ADPb; and results of 
automated CBC analysisc within reference intervals. The study protocol was approved by the Animal 
Ethics Committee of Murdoch University. 
Blood sample collection and processing—The skin over a jugular vein was aseptically prepared for 
venipuncture in all dogs. A 21-gauge butterfly catheter was placed in the prepared vein through a 
stab incision and connected to allow blood collection (4.5 mL) into each of 4 evacuated tubes 
containing 3.2% trisodium citrate. The first tube in each set was discarded, and the remaining 13.5 
mL of citrated whole blood was used for the experiment. 
Each citrated whole blood sample was diluted with 6% HES 130/0.4,d 10% HES 200/0.5,e and saline 
solution at a ratio of 1:9 (0.2 mL of solution to 1.8 mL of whole blood) and 1:3 (0.5 mL of solution to 
1.5 mL of whole blood) and was maintained at 38.0°C in a water bath. Within 2 hours after sample 
collection, Ct for each diluted blood sample was measured with the platelet function analyzer and 
collagen and ADP–coated cartridges in duplicate. When duplicate measurements had a covariance > 
15%, or when the analyzer indicated an error such as flow obstruction, a new sample at the same 
dilution was created, and a repeated measurement was made. Results that had a covariance > 15% 
were then excluded from analysis. 
Statistical analysis—Closure time was used as the response variable of interest, and values were 
assessed for a normal distribution with the Shapiro-Wilk test. Because the test revealed that the 
values were not normally distributed, Cts were reported as median (IQR). Reciprocal transformation 
resulted in a normal distribution, so 1/Ct was used for the response variable in statistical tests. A 
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generalized linear mixed model was developed by use of statistical software,f with fixed effects of 
solution (3 levels) and dilution (3 levels) and a random effect for dog. When a significant (P < 0.05) 
interaction of solution and dilution was identified, post hoc comparisons were performed across 
solutions and dilutions with the least squares means method and Bonferroni correction, with values 
of P < 0.005 considered significant. 
3.4. Results 
Blood samples were successfully collected from all 10 healthy dogs and were processed in 
accordance with the experimental protocol. The median predilution PCV was 48% (IQR, 42% to 50%), 
and platelet count was 276 X 109 cells/L (IQR, 192 X 109 cells/L to 440 X 109 cells/L). The PCV and the 
platelet count of all blood samples diluted with saline solution remained > 32% and > 86 X 109 
cells/L, respectively (Table 3-1). One blood sample diluted 1:9 with saline solution was excluded 
from statistical analysis because of a dilution error. 
A dilutional effect on Ct was identified for the 1:3 dilution, compared with the 1:9 dilution, for each 
type of solution tested, but only samples diluted with HES 200/0.5 had an increase in Ct beyond a 
dilutional effect at the 1:3 dilution (P = 0.002). No effect of HES or dilution on Ct was evident for the 
1:9 dilutions (Table 3-2). Fourteen of the 140 (10%) measurements needed repeated measurement 
because of a high covariance or machine error; however, no sole measurement was repeated more 
than twice. 
Table 3-1 - Median (IQR) PCV and platelet count for 1:3 and 1:9 dilutions with 0.9% NaCl solution of 
whole blood samples from 10 healthy dogs. 
Dilution PCV (%) Platelet count (X109 cells/L) 
None 48 (42–54) 276 (192–440) 
1:9 41 (30–50) 243 (100–288) 
1:3  36 (32–42) 213 (86–326) 
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Table 3-2 - Median (IQR) platelet Ct for 1:3 and 1:9 dilutions with 0.9% NaCl solution, HES 130/0.4, 
and HES 200/0.5 of whole blood samples from 10 healthy dogs. 
Dilution 0.9% NaCl HES 130/0.4 HES 200/0.5 
None 70 (66–73)A 70 (66–73)
A 70 (66–73)A 
1:9 71 (62–83)a,A 83.5 (71–91)
a,B 80.5 (73–84)a,A 
1:3 92 (85–100)a,B 101 (94–112)
a,b,C 125 (118–140)b,B 
a–cWithin a row, values with the same superscript letter are not significantly (ie, P ≥ 0.005; Bonferroni 
corrected) different. A–CWithin a column, CTs with the same superscript letter are not significantly 
(ie, P ≥ 0.005; Bonferroni corrected) different. The reference interval used for CT was 52 to 86 
seconds.14 
 
3.5. Discussion 
The present study revealed that a 1:3 dilution of canine blood with HES 200/0.5 but not HES 130/0.4 
led to an increase in platelet Ct beyond a dilutional effect. This in vitro dilution was chosen to mimic 
the dilution achieved in vivo through IV administration of a fluid bolus of 30 mL/kg, ignoring 
redistribution and excretion in dogs. Findings suggested that HES 130/0.4 had less of an adverse 
effect on platelet function than did HES 200/0.5. We also found that a 1:3 dilution resulted in an 
increase in Ct beyond the upper reference limit, no matter which solution was used. The increase in 
Ct associated with dilution with any solution can be explained by a decrease in PCV and platelet 
count. A negative relationship between Ct and PCV in dogs has been described.14,16 Changes in Hct 
can affect platelet function because of changes in blood flow dynamics altering platelet interaction 
with the endothelium,23 which may also hold true for contact with the aperture of the platelet 
function analyzer used, as well as a decrease in ADP release from erythrocytes.24 A decrease in 
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platelet count may have also contributed to the increase in Ct in the diluted samples in the present 
study, which has been identified in previous studies14,16 involving dogs. This effect may have been 
enhanced by dilution of von Willebrand factor.25  Several theories may explain the mechanism by 
which HES 200/0.5 dilution caused platelet dysfunction in the present study, including binding of von 
Willebrand factor,26,27 HES molecules coating platelet surfaces, and a decrease in expression of 
platelet surface protein integrin αIIbβ3, which all may reduce platelet adhesion and aggregation.28 
An in vitro study18 of human platelet function revealed a decrease in expression of integrin αIIbβ3 
receptor with dilutions involving HES 200/0.5 but not HES 130/0.4.18 The differences identified  
between HES 200/0.5 and HES 130/0.4 might be related to solution-specific pharmacological 
properties, in particular molecular weight and molar substitution.27,29 The molecular weight of an 
HES solution is the mean manufactured molecular weight of the polydispersed solution, and the 
molar substitution is the number of hydroxyl groups substituted with hydroxyethyl groups on the 
glucose subunit of HES molecules.29 Hydroxyethyl starch solutions of higher molecular weight and 
molar substitution have a slower rate of degradation and excretion in vivo than do other HES 
solutions, and this phenomenon has commonly been cited as the main reason that treatment with 
these solutions causes greater platelet dysfunction.29,30 However, these pharmacokinetic properties 
may not be relevant to in vitro studies. It is possible that cleaving of HES molecules by amylase may 
still occur in vitro, as it does in vivo, decreasing the HES molecular weight within the sample; 
therefore the rate of degradation may still be relevant. Some evidence exists that high molar 
substitution can considerably affect the degree of whole blood coagulation in vitro, independent of 
molecular weight.31 But there is little evidence regarding the effect of differences in molecular 
weight and molar substitution, independent of each other, on platelet function specifically in vitro. 
Another property related to a slower rate of HES degradation and greater platelet dysfunction is a 
high C2:C6 ratio; 31 however, this was unlikely to be applicable in the present study given that HES 
200/0.5 has a lower C2:C6 ratio (5:1) than does HES 130/0.4 (9:1). The present study did not 
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elucidate the exact mechanisms of HES-induced platelet dysfunction, given that it was designed only 
to determine whether platelet dysfunction occurred, as detected by the platelet function analyzer. 
One additional difference between the 2 HES solutions evaluated was the concentration of HES. The 
HES 200/0.5 solution had a greater concentration of HES molecules (10%), compared with HES 
130/0.4 (6%). The 10% solution was chosen for comparison because it is the solution available for 
clinical use in Australia. Although it is unknown which solution had the greater number of HES 
molecules because of the polydiversity among brands and individual bags of solution, HES 200/0.5 
may have provided more individual HES molecules, enhancing platelet dysfunction. Such differences 
between solutions also create variations in the degree of redistribution in vivo, such as differences in 
plasma volume expansion, degrees of dilution of blood constituents, and rates of clearance.32,33 
These variations contribute to the challenge of designing in vivo studies, not only in interpreting 
differences between solutions but also in the ability to select a valid control solution for comparing 
the effect of dilution, given that crystalloid solutions have a different pattern of distribution. 
Therefore, in vitro studies such as the present study, although limited by many factors including the 
absence of any platelet interaction with the endothelium, also have an advantage in that the effect 
of various solutions can be compared without the complicating factors of redistribution and 
metabolism. Other complicating factors common to in vivo studies designed to assess the effect of 
HES solutions on platelet function include variability in doses used, differences in the disease status 
of patient populations, and choice of method of platelet function analysis, making comparisons of 
findings across studies difficult. We chose 1:9 and 1:3 dilutions with the aim of indirectly comparing 
results of the present study with those of another study,6 which demonstrated that whole blood 
diluted with HES 670/0.75 led to an increase in CT beyond a dilutional effect when a 1:3 but not 1:9 
dilution was used. The 1:9 dilution mimicked a 10 mL/kg bolus dose and the 1:3 dilution mimicked a 
30 mL/kg bolus dose administered IV to a dog with an estimated blood volume of 90 mL/kg (ie, 
euvolemia). The effect of the same in vitro dilutions on Ct in dogs was investigated in another 
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study22 involving an HES solution of low molecular weight and molar substitution, HES 130/0.42, 
which has some differences in properties compared with HES 130/0.4. A significant increase in Ct 
was identified with HES 130/0.42 diluted 1:3 with canine whole blood beyond a dilutional effect, 
which differs from our findings, despite the 2 solutions being very similar. Several factors could 
account for this difference. Hydroxyethyl starch 130/0.4 is a waxy, maize based colloid, whereas HES 
130/0.42 is a potato-based colloid. The 2 solutions also differ in molar substitution, which may 
account for the difference in Ct. A conservative value of P < 0.005 was used for pairwise comparisons 
made in our study to reduce type I error, which may have precluded detection of more differences 
than were identified. Differences in study subjects and subject numbers as well as a lower 
predilution Ct in our study may have also contributed to different results. For comparison, an in vitro 
study3 in humans compared the effect on coagulation between these 2 solutions through use of 
thromboelastography and platelet aggregometry and found no difference between the solutions, 
but HES 130/0.4 and HES 130/0.42 have not been compared directly in dogs. 
The clinical relevance of the effect of HES solutions with low molecular weight and molar 
substitution on platelet function in humans remains controversial despite the abundance of 
literature on the topic. Early in vitro studies indicated that blood samples diluted with HES 130/0.4 
caused less platelet dysfunction as measured through various techniques such as platelet 
aggregometry,4,34 Ct analysis,4,5,18 and flow cytometry,18 compared with that caused by HES solutions 
of higher molecular weight and molar substitution. However, several clinical trials1,20,21 comparing 
the effects of HES 130/0.4 with HES 200/0.5 on blood loss and transfusion requirements in  
orthopedic surgery, cardiopulmonary bypass patients, and intensive care patients have yielded 
conflicting evidence, compared with the in vitro studies. Meta-analyses and literature reviews1,20,21 
have shown that no conclusion can be made regarding the benefit of administration of HES 130/0.4 
versus HES 200/0.5 or crystalloid solutions in humans because of the small sample sizes and the 
quality of these human trials and because several reports were retracted for scientific misconduct. In 
addition, although the manufacturers of HES 130/0.4 have recommended a dose limit of 50 mL/kg/d, 
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the European Society of Intensive Care Medicine released a consensus statement, in which no dose 
recommendations for HES 130/0.4 could be made given the minimal evidence for its safety 
regarding blood loss, acute kidney injury, and risk of death.35 Most recently, the Surviving Sepsis 
Campaign consensus statement has recommended against the use of HES solutions in septic human 
patients because of the lack of clear benefit and evidence of harm caused to patients,36 but large 
clinical trials have yet to be performed in veterinary medicine. 
The present study demonstrated that dilution of canine blood samples 1:3 with saline solution, HES 
130/0.4, and HES 200/0.5 led to an increase in Ct attributable to a dilutional effect alone.  
Hydroxyethyl starch 200/0.5, however, led to an increase in Ct beyond a dilutional effect when 
diluted 1:3 with blood, consistent with platelet dysfunction. Interestingly, we found that HES 130/0.4 
did not cause platelet dysfunction at this same dilution, which suggests that this solution may be a 
superior choice when platelet dysfunction is of concern. However, in vivo studies are warranted to 
investigate the risk of clinical use of this solution in dogs. 
 
3.6. Footnotes 
a.  Platelet Function Analyzer-100, Dade Boehring Inc, Miami, Fla. 
b.  Dade PFA Collagen/ADP Test Cartridge, Siemens Healthcare, Marburg, Germany. 
c.  ADVIA 120 hematology system, Bayer Diagnostics Mfg Ltd, Dublin, Ireland. 
d.  Voluven 6% (hydroxyethyl starch 130/0.4), Fresenius Kabi Deutschland GmbH, Friedberg, 
Germany. 
e.  Starquin 200 10%, Biomed Ltd, Point Chevalier, Auckland, New Zealand. 
f.  SAS, version 9.3, SAS Institute Inc, Cary, NC. 
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4. Chapter 4: PLATELET CLOSURE TIME IN ANESTHETIZED DOGS WITH HEMORRHAGIC SHOCK 
TREATED WITH HYDROXYETHYL STARCH 130/0.4 OR 0.9% NACL 
 
4.1 Abstract 
Objective - Hydroxyethyl starch (HES) 130/0.4 is used to treat shock in dogs. This study measured 
platelet closure time (PCT) in dogs during hemorrhagic shock and after HES 130/0.4 or 0.9% NaCl 
administration.  
Animals - Eleven healthy greyhounds  
Procedure - Dogs were anesthetized and 48mL/kg of blood removed to induce hemorrhagic shock. 
Dogs received 20 mL/kg of HES 130/0.4 (n=6) or 80 mL/kg of 0.9% sodium chloride (NaCl) (n=5) 
intravenously over 20 minutes. Platelet closure time was measured using the Platelet Function 
Analyser-100 with collagen and adenosine-diphosphate cartridges at: T0 = 60 minutes after 
induction of anesthesia prior to hemorrhage, T1 = during hemorrhagic shock and T2 = 40 minutes 
after completion of fluid bolus. Packed cell volume (PCV) and platelet count were concurrently 
measured.  
Results - Hemorrhagic shock did not significantly change PCT, with no difference between T0 and T1. 
Both the HES 130/0.4 and 0.9% NaCl group had a significantly increased mean PCT at T2 to 91.4 
seconds (95% CI 69.3-113.4) and 95.5 seconds (95% CI 78.2-112.8), respectively, compared to T1. 
The magnitude of change was significantly greater for the 0.9% NaCl group than the HES 130/0.4 
group. There was no difference in the magnitude of change in PCV and platelet count between the 
two groups. The PCV and platelet count were > 25% and > 100,000/µL respectively in all dogs, except 
for dogs in the HES 130/0.4 group at T90 where platelet counts were <100,000/µL. 
Conclusion and Clinical Relevance - Hemorrhagic shock in greyhounds under anesthesia did not 
cause a significant change in PCT. Both HES 130/0.4 and 0.9% NaCl administration after induction of 
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shock increased PCT. These results do not support that HES 130/0.4 causes relevant platelet 
dysfunction beyond hemodilution, however, this study did not assess risk of bleeding.  
 
4.2 Introduction 
The use of hydroxyethyl starch (HES) solutions for the treatment of shock is controversial because of 
adverse effects reported on both human1-5 and canine6-8 platelet function, and its association with 
increased intra-operative blood loss and transfusion requirements in people.1,9-12 Many studies 
support that these complications are associated with HES solutions of high molecular weight (MW) 
and high molar substitution (MS).5,6,13 Therefore, the use of HES 130/0.4, with a low MW of 130 KDa 
and a low MS of 0.4, has become more commonplace in people due to its minimal effect on platelet 
function.2,13,14 However, there is some contradicting evidence that platelet dysfunction still occurs 
with HES 130/0.4.4,5 
Studies investigating the use of HES solutions in dogs have most commonly used the Platelet 
Function Analyzer-100 (PFA-100) to measure platelet function.6,7,15 It measures platelet closure time 
(PCT), which is the time taken in seconds for a small aperture, to be closed by platelet plug 
formation.16 An increased PCT indicates platelet dysfunction, however, dilution of blood that 
decreases hematocrit (< 25% – 30%17-19) and platelet count (< 100,000 platelets/µL19) can also 
increase PCT. 
There have been two recent in vitro studies using the PFA-100 to assess the effect of low MW and 
low MS HES solutions on canine platelet function.15,20 One study using HES 130/0.42 found that it 
caused a mild prolongation in PCT20 whereas one using HES 130/0.4 found no effect.15 As in vitro 
studies cannot assess the pharmacokinetic and pharmacodynamic effects of these fluids, and 
exclude any platelet interaction with the endothelium, it is unknown to what degree HES 130/0.4 
may have on canine platelet function in vivo. Also, these solutions are usually used in dogs suffering 
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from shock and it has been found in people that trauma-induced shock can cause platelet 
dysfunction itself.21-24 Therefore, shock may further enhance any platelet dysfunction that HES 
130/0.4 causes. 
The objective of this study was to determine if hemorrhagic shock increases PCT above baseline in 
anesthetized greyhounds. The secondary objective was to determine if 20 mL/kg of HES 130/0.4 
increases PCT beyond the effect of hemorrhagic shock or hemodilution.  
 
4.3 Materials and methods 
This study was approved by the university’s Animal Ethics Committee. Eleven healthy adult 
greyhound dogs were included in this study. Dogs were healthy based on physical examination and 
complete blood count. The dogs were not fasted and had free access to water. Each dog was 
randomized to receive either HES 130/0.4 (treated group, n = 6) or 0.9% sodium chloride (NaCl) 
(control group, n = 5) according to an assigned sealed envelope. 
The dogs were premedicated with 0.2mg/kg of methadonea given intramuscularly. Thirty minutes 
after premedication, a 20-gauge 1-inch over-the-needle catheter was aseptically placed in the right 
cephalic vein, and anesthesia was induced with 2.5mg/kg of alfaxaloneb given intravenously. Animals 
were placed in left lateral recumbency, orotracheally intubated and anesthesia was maintained with 
isofluranec and 100% oxygen via a circle breathing system. Vaporiser settings were adjusted to 
achieve an end-tidal isoflurane concentration of 1.4% measured using an agent monitor.d 
Mechanical ventilation was provided using a volume controlled time cycled ventilatore at a rate of 10 
breaths per minute with an initial tidal volume of 20 mL/kg, which was subsequently adjusted if 
required during the instrumentation period to achieve a PaCO2 of 35-40 mmHg. No further 
adjustment was made throughout the remainder of anesthesia. Hartmann’s solutionf was 
administered via the cephalic catheter at a rate of 10 ml/kg/hr until the time of administration of the 
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treatment or control solutions. A 12-gauge 6-inch over-the-needle catheter was aseptically placed in 
the right jugular vein, with the distal end measured beyond the thoracic inlet. A 14-gauge 4-inch 
over-the-needle catheter was surgically placed in the left femoral artery. The catheters were 
connected via fluid filled transducersg to a multivariable monitorh and calibrated to atmospheric 
pressure. Heart rate (HR), electrocardiogram, central venous pressure, and pulse oximetry were 
monitored with a multivariable monitor throughout the experiment. Body temperature was 
maintained between 36°C and 38°C by applying warm air to the upper surfaces of the dog.i 
Sixty minutes after induction of anesthesia, hemorrhagic shock was induced by removing 48 mL/kg 
of blood over a 30 minute period from the femoral arterial catheter. A pilot study in greyhounds 
using the same anesthetic protocol was performed prior to this study, which determined that 
removal of 48 mL/kg of blood induced shock, as assessed by an increase in HR, a direct MAP of less 
than 60 mmHg, and an increase in oxygen extraction ratio (O2ER). 
Immediately after 48 mL/kg of blood was removed, intravenous Hartmann’s solution administration 
was discontinued and the dogs received either 20 mL/kg of HES 130/0.4j or 80 mL/kg of 0.9% NaCl 
over 20 minutes. Hydroxyethyl starch 130/0.4 was delivered by a pressure bag via the cephalic 
catheter and 0.9% NaCl was delivered by 2 pressure bags via the cephalic and jugular catheters. The 
pressure applied to the pressure bags was monitored throughout to ensure the fluid was delivered 
continuously during the 20 minute period.  
Cardiac output (CO) was measured by the lithium dilution cardiac outputk technique as previously 
described,25 with modification of the dose of lithium chloride to 0.005 mmol/kg and withdrawing 
blood via the femoral artery. Measurements were made in duplicate. When two results varied more 
than 15%, repeated measurements were made and the results varying more than 15% were 
excluded from analysis.   
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Blood was collected simultaneously from the femoral arterial and jugular venous catheters into 
lithium heparin syringes, and blood gas analysisl was performed within 5 minutes of blood collection. 
Venous blood was collected from the jugular venous catheter into sodium citrate tubes for the 
measurement of PCT. Platelet closure time was measured in duplicate using the PFA-100,m with 
collagen and adenosine diphosphate cartridgesn and co-variance of less than 15% between 
measurements were accepted. Where duplicate measurements had a co-variance of greater than 
15%, or if the analyzer indicated an error such as flow obstruction, measurement was repeated using 
the same sample and the two closest samples with a CV < 15% were included. Platelet closure time 
was measured at three time points: T0, at base line during general anesthesia immediately prior to 
hemorrhage; T1, during hemorrhagic shock, which was immediately after removing 48 mL/kg of 
blood; and T2, 40 minutes after completion of fluid administration (Figure 1).  
Data also collected simultaneously at these time points included HR, direct MAP, arterial and venous 
blood gas, hemoglobin concentration (Hb), PCV, and CO. At the conclusion of data collection, 
euthanasia was performed using intravenous pentobarbital in accordance with the ethics committee 
approved protocol. The O2ER was calculated at each time point using the formulae in Table 1.  
Statistical analysis - For assessment of the effect of shock on PCV, platelet count, O2ER and PCT, 
paired comparisons were made across all greyhounds for data at T0 vs T1 using a paired t-test.   
For assessment of the effect of fluid therapy on PCV, platelet count, O2ER and PCT, comparisons 
were made across both treatment groups for data at T1 vs T2 using a paired t-test. Where both 
treatments had a similar result (i.e. increase or decrease), the magnitude of the change was 
compared between treatments using an unpaired t-test with a Satterthwaite adjustment for unequal 
variances when indicated. Significance was determined at p < 0.05 for all tests. SAS v 9.3 was used 
for the analysis (SAS Institute, Cary, NC). 
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Figure 4-1 - Time points for platelet closure time measurements: T0, at base line during general 
anesthesia immediately prior to hemorrhage; T1, during hemorrhagic shock, which was immediately 
after removing 48 mL/kg of blood; and T2, 40 minutes after completion of fluid administration of 
either hydroxyethyl starch (HES) 13/0.4 or 0.9% sodium chloride (NaCl).  
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Table 4-1 - Formulae for calculated variables49 
Calculated variable  
(units) 
Symbol Formula 
Arterial oxygen content  
(mL/dL) 
CaO2 (1.34 x [Hb] x SaO2) + (0.003 x PaO2) 
Venous oxygen content  
(mL/dL) 
CvO2 (1.34 x [Hb] x SvO2) + (0.003 x PvO2) 
Cardiac index  
(L/minute/m2) 
CI CO/BSA 
Oxygen delivery index 
(mL/minute/m2) 
DO2 CaO2 x CI x 10 
Oxygen consumption index 
(mL/minute/m2) 
VO2 (CaO2 – CvO2) x CI x 10 
Oxygen extraction ratio  
(%) 
O2ER VO2/DO2 x 100 
Body surface area  
(m2) 
BSA 10.1 × body weight (kg)0.67/100  
 
BSA, body surface area; CO, cardiac output; Hb, hemoglobin concentration; PaO2, partial pressure of 
oxygen in arterial blood; PvO2, partial pressure of oxygen in venous blood; SaO2, hemoglobin 
saturation in arterial blood; SvO2, hemoglobin saturation in venous blood.  
 
4.4 Results 
Five entire male and 6 entire female greyhounds were used in this study. The mean body weight was 
28.3kg (SD 3.3kg), and the mean age was 3.7 years (SD 1.8 years). Two dogs in the HES 130/0.4 
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group had PCTs and platelet count at T2 excluded from analysis due to platelet clumping in the 
sample.  
The first objective was evaluated across all dogs. There was no significant change in PCT at T1, 
compared to T0 (Table 2). There was a significant decrease in PCV and platelet count, and a 
significant increase in O2ER, at T1 compared to T0 (Table 2), consistent with hemorrhagic shock.  
The second objective was evaluated across treatment groups. Both groups had a significant increase 
in PCT at T2, compared to T1 (Table 3). The magnitude of change was significantly greater in the 
0.9% NaCl group compared to the HES 130/0.4 group. Both groups had a significant decrease in PCV, 
platelet count and O2ER at T2, compared to T1 (Table 2), however, the magnitude of change was not 
significantly different between the two groups.  
The PCV of all dogs at each time point was > 25%. All platelet counts where > 100,000/µL, except for 
dogs in the HES 130/0.4 group at T2 where platelet counts were < 100,000/µL. 
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Table 4-2 - Mean (95% confidence interval) packed cell volume, platelet count, oxygen extraction 
ratio (O2ER) and platelet closure time in greyhounds under general anesthesia (T0) and thirty 
minutes after 43mL/kg of blood loss (T1).  
Variable T0 T1 P value* 
Packed cell volume (%) 
 
49.3  
(47.5 - 51.0) 
46.9  
(45.4 - 48.5) 
0.0125 
Platelet count               
(X109 cells/L) 
 
172  
(158 - 186) 
149.5  
(131.3 - 167.8) 
0.0001 
O2ER  (%) 
 
8.80  
(6.90 - 10.5) 
60.0  
(48.1 - 70.9) 
<0.0001 
Platelet closure time+ 
(seconds) 
87.7  
(69.6 - 105.8) 
70.4  
(61.7 - 79.0) 
0.0805 
* Values less than 0.05 were considered significant 
+The greyhound reference interval for platelet closure time is 63 to 92 seconds48 
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Table 4-3 - Mean (95% confidence interval) of packed cell volume, platelet count, oxygen extraction 
ratio (O2ER) and platelet closure time in greyhounds in hemorrhagic shock (T1), under general 
anesthesia, that then received either 20 ml/kg of hydroxyethyl starch (HES) 130/0.4 or 80 ml/kg of 
0.9% sodium chloride (NaCl) (T2).  
Variable Group T1 T2 P value* Magnitude of 
change (P value*) 
Packed cell 
volume (%) 
HES 46.3  
(44.3 - 48.4) 
29.8  
(28.4 - 31.2) 
<0.0001 0.766 
NaCl 47.6  
(44.2 - 51.0) 
30.6  
(26.7 - 34.5) 
0.0002 
 
Platelet count 
(X109 cells/L) 
HES 133 
(111 - 154) 
69.5  
(28.9 - 110)  
0.0023 0.065 
NaCl 170 
(144 - 195) 
128 
(110 - 146) 
0.0072 
 
O2ER (%) 
HES 68 
(61 - 75) 
9 
(4 - 14) 
<0.0001 0.056 
NaCl 49  
(24 - 75) 
10  
(5 - 16) 
0.0071 
 
Platelet closure 
time (seconds) 
HES 75.1  
(59.0 - 91.4) 
91.4  
(69.3 - 113.4) 
0.0443 0.0421  
NaCl 64.6  
(56.9 - 72.3) 
95.5  
(78.2 - 112.8) 
0.0077 
* Values <0.05 were considered significant 
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4.5 Discussion 
This study demonstrated no change in PCT during shock but a significant increase in PCT after 
administration of 20 mL/kg of 6% HES 130/0.4 and 80 mL/kg of 0.9% NaCl. Interestingly, we found 
that the magnitude of change in PCT was greater after 0.9% NaCl administration, compared to HES 
130/0.4 administration. This result does not support that HES 130/0.4 causes platelet dysfunction 
beyond the effect of hemodilution.  
The lack of significant change in PCT during shock in this study is contrary to the majority of recent 
studies in people that found platelet dysfunction to occur during hemorrhagic shock secondary to 
trauma.21-24,26,27 However, one study in people showed a decrease in PCT immediately following 
traumatic hemorrhage, which corresponded with increased platelet reactivity measured by flow 
cytometry.28 Blood samples were collected immediately following trauma in this one study while 
blood samples in most previous studies were collected later in the emergency room. Our study also 
chose an early time point in shock to measure PCT, however the fluctuation in PCT that we observed 
was not statistically significant. 
We used O2ER as an objective measure of shock, as several studies have demonstrated a significant 
increase in O2ER during severe shock.
26,29,30 An increase in O2ER reflects decreasing oxygen delivery, 
despite oxygen consumption staying relatively constant. An O2ER greater than 60% is generally 
considered a marker of severe shock, as this is the time at which oxygen consumption starts to 
depend on oxygen delivery, depending on the underlying cause of shock. In our study, there was a 
moderate to marked increase in O2ER, and all dogs were tachycardic and hypotensive, supporting 
the presence of shock. The increase in O2ER was not as marked as expected in all individuals, given 
the volume of blood loss. This may be due to individual variability, or due to measuring the 
parameter in early shock, where good cardiovascular compensation is still intact. Another reason for 
this difference may be due to the greyhound breed utilized in our study. Although O2ER has not been 
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compared between greyhounds and non-greyhound breed dogs, cardiovascular function31 and 
oxygen carrying capacity32 are known to be different. 
We found a minor, but significant, increase in PCT with both types of fluid administration, which can 
be explained by hemodilution. A negative relationship between PCT and PCV has been previously 
described in dogs.18,19 Changes in hematocrit can affect platelet function due to changes in blood 
flow dynamics altering platelet interaction with the endothelium,33 as well as decreased ADP release 
from red blood cells.34 The effect of dilution on PCT may also be due to dilution of von Willebrand 
Factor.35 In our study, a decrease in platelet count may have also contributed to the increased PCT, 
which has been described previously in dogs.18,19 It is interesting that the magnitude of change in 
PCT was greater in the 0.9% NaCl group, which seems unlikely to be due to greater hemodilution, as 
there was no significant difference in PCV or platelet count between the groups. However, dilution 
of other factors that may affect PCT, such as von Willebrand Factor, were not measured.  
In contrast to previous studies using higher MW and MS HES solutions,6,7 our study found that HES 
130/0.4 did not significantly increase PCT, compared to 0.9% NaCl. Hydroxyethyl starch solutions 
with a high MW and MS are known to have a direct adverse effect on platelet function in people, the 
mechanisms of which have been described elsewhere.14,36,37 Previous studies in dogs showed HES 
670/0.75 to cause platelet dysfunction as demonstrated by an increased PCT in vitro6 and in vivo.7 In 
another study, HES 200/0.5 (medium MW and MS) diluted 1:3 with canine whole blood increased 
PCT in vitro, however HES 130/0.4 at this same dilution did not increase PCT beyond dilutional 
effect. 15 This finding supports our result.  In contrast, HES 130/0.42 diluted 1:3 with canine whole 
blood increased PCT beyond dilutional effect in vitro.20 However, the different properties of HES 
130/0.42 make direct comparisons with HES 130/0.4 difficult.  
The failure to cause a significant change in PCT with HES 130/0.4, beyond hemodilution, may be due 
to use of a 20 mL/kg dose in our study. A 1:4 dilution of HES 130/0.4 with canine whole blood caused 
greater abnormalities in coagulation, as measured by thromboelastometry, compared with a 1:10 
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dilution, which suggests a dose dependent effect on coagulation.38 This study did not assess platelet 
function specifically. We chose a dose of 20 mL/kg of HES 130/0.4, attempting to match the 80 
mL/kg dose of isotonic crystalloid solution,39,40 as it is a common large bolus dose for the treatment 
of shock in dogs.41 As we chose this single dose we cannot comment if HES 130/0.4 has a dose 
dependent adverse effect on PCT.  
There are some limitations to this study. The shock model used in this study induced hemorrhagic 
shock with minimal trauma by removing a fixed volume of blood in a controlled manner. This model 
is applicable to situations of large volumes of blood loss under general anesthesia.  The model is not 
directly applicable to animals with systemic inflammatory response syndrome, sepsis or trauma 
where there is likely cytokine release, which may affect the result.  
The results of this study may only be referent to greyhounds. Greyhounds are known to have a 
higher PCV, resulting in higher blood viscosity, and a lower platelet count.42-44 Some greyhounds are 
also known to have significant post-operative bleeding, related to increased fibrinolysis45 or reduced 
fibrin cross link formation and clot strength, as measured by thromboelastography.46,47 Despite 
postoperative bleeding, PCTs were found to be normal in one study.46 Platelet closure time has also 
been validated in greyhounds with their own established reference interval.48 These findings suggest 
that the greyhound breed-specific variability in coagulation should not heavily influence the PCT. 
We did not have a control group that did not receive fluid resuscitation, therefore we do not know if 
PCT would have changed over time under general anesthesia or due to prolonged shock. We cannot 
determine if the changes we saw in PCT after treatment with fluid resuscitation were due to 
hemodilution or the late effects of shock. Inclusion of a group that were resuscitated with auto-
transfused fresh whole blood may have answered this question.  
In conclusion, we demonstrated that hemorrhagic shock did not cause platelet dysfunction, as 
measured by PCT, in greyhounds under general anesthesia. We found that 20 mL/kg of HES 130/0.4 
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and 80 mL/kg of 0.9% NaCl administered over a 20 minute period significantly increased PCT. The 
magnitude in increase of PCT was greater with 0.9% NaCl administration, indicating HES 130/0.4 
does not cause platelet dysfunction beyond a dilutional effect. Although the changes in PCT were 
significant, they were minor, therefore may not be clinically relevant. However, this study did not 
assess the risk of bleeding due to platelet dysfunction. 
 
4.6. Footnotes 
a Methone, Parnell Australia Pty Ltd, NSW, Australia 
b Alfaxan, Jurox Pty Ltd, NSW, Australia 
c ISO Veterinary Companies of Australia, NSW, Australia 
d Capnomac Ultima, Datex-Ohmeda Medical supplies Australia, NSW, Australia 
e  Model TH-1 Beijing Read Eagle Technology Co Ltd, Beijing, China 
f Baxter Healthcare Pty Ltd Australia, NSW, Australia 
g  DTX PlusTM Argon Critical Care Systems, Singapore 
h Surgivet V9203 Sound Medical, VIC, Australia 
I Bair Hugger warming unit Model 505, Critical Assist, VIC, Australia 
j Voluven 6% (hydroxyethyl starch 130/0.4), Fresenius Kabi Deutschland GmbH, Friedberg, 
Germany 
k LiDCO Cardiac Sensor Systems, LiDCO Ltd, London, UK 
l  ABL 725 Radiometer Pacific Pty Ltd, VIC, Australia 
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m Platelet Function Analyzer-100, Dade BoehringInc, Miami, Florida, USA 
n Dade PFA Collagen /ADP Test Cartridge, Siemens Healthcare, Marburg, Germany 
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5. Chapter 5: SUMMARY AND CONCLUSION 
We found that HES 200/0.5 causes canine platelet dysfunction, as measured by the PFA-100 in vitro 
at a 1:3 dilution with saline, however HES 130/0.4 did not. We also found that in a greyhound 
haemorrhagic shock model, 20 ml/kg of HES 130/0.4 administered rapidly to treat shock did not 
cause platelet dysfunction beyond the effects of dilution. This is consistent with the reports from 
people, where higher MW and MS solutions has a greater risk of causing platelet dysfunction 
compared with lower MW and MS solutions.48 
Our findings are an important addition to the literature as they are specific to canine platelet 
function. Previous studies have shown that HES 670/0.75 causes platelet dysfunction in dogs in vitro 
and in vivo25,26 and, although direct comparisons cannot be made with our study, our findings 
suggest that HES 130/0.4 would be a more ideal solution to use if platelet dysfunction and 
haemorrhage were of concern. 
Some of the limitations of our studies are that only one platelet function test, CT measured by the 
PFA-100, was utilised, and multiple methods of platelet function analysis would be ideal in order to 
investigate the mechanisms of platelet dysfunction. In addition, there were some difficulties in 
measuring platelet function with the PFA-100, due to mechanical errors and result variability. We 
minimised these errors by ensuring duplicate measurements were made with minimal covariance, 
however, it became obvious during the study that use of this equipment requires excellent sample 
handling. This was especially a problem with the in vitro study, where 14% of samples had to be 
repeated. One of the reasons for this may have been that samples for the in vitro study required 
more delay before analysis, to allow mixing with solutions, which may have led to platelet clumping. 
Another possibility is that, as the in vivo study was performed after the in vitro study, the technique 
for sample handling may have improved. In future studies, the research group will be analysing 
samples in triplicate in order to avoid having to repeat samples when there is a mechanical error and 
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improve accuracy of results. This will also avoid the bias of discarding the result that has the larger 
covariance.  
It is unclear how our results apply to dogs requiring colloid support for disease. The first study was in 
vitro and may not replicate the clinical situation. The second study was an in vivo study, but is 
specific to a haemorrhagic shock model under general anaesthesia. Therefore, the results from this 
study may be applicable to haemorrhage associated with surgery but may not apply to animals 
sustaining trauma in which tissue injury and inflammation may interfere with platelet function. It is 
also unknown what the effect of anaesthetic agents such as isoflurane have on platelet function in 
dogs.  An additional limitation of the in vivo study is the use of greyhounds. Although the PFA-100 
has been validated in greyhounds,19 as discussed in chapter 3, results may differ from those  in non-
greyhound breed dogs. 
Further studies are warranted to investigate the clinical applicability of our results. Unfortunately, 
there is no single platelet function or coagulation test that predicts bleeding in dogs or people and 
the volume of bleeding can be difficult to determine. Therefore, it would be difficult to determine if 
bleeding occurs with the use of HES 200/0.5, or even HES 130/0.4, despite the findings of our results. 
Large scale clinical trials would be required to determine the risk of haemorrhage in dogs with 
trauma, surgery, and those at risk of coagulopathies with the use of HES 130/0.4.  
It is also important to address other potential risks of HES solutions in dogs; most importantly acute 
kidney injury, which is a serious concern in people with sepsis.100,127-129 Future studies are justified to 
determine if HES solutions cause acute kidney injury in dogs, and if this risk is clinically relevant. If it 
does, the canine model may be of use in determining the mechanism of kidney injury, as this 
information is currently sparse in the human literature also.  
Despite our limited understanding of the effects of HES solutions in dogs, based on the results of our 
study and those to date in the literature, there should be some caution using HES solutions in dogs 
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at risk of coagulopathy and kidney injury, and in dogs in septic shock. If choosing a HES solution, our 
findings suggest there would be some benefit in using a lower MW and MS solution such as HES 
130/0.4, as it appears to cause less platelet dysfunction, which may reduce the risk of ongoing 
haemorrhage. 
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APPENDICES 
Appendix A: Chapter 3 raw data – closure times 
Closure times (CT) of all dogs (no dilution), and in vitro CTs of respective blood with one in nine 
dilution (1:9) and one in three (1:3) dilution, with each of the following solutions: 0.9% sodium 
chloride (NaCl), hydroxyethyl starch (HES) 130/0.4, and HES 200/0.5.  
Dog number Solution Concentration CT (seconds) 
1 No dilution 69 
1 No dilution 65 
1 0.9% NaCl 1:9 58 
1 0.9% NaCl 1:9 56 
1 0.9% NaCl 1:3 79* 
1 0.9% NaCl 1:3 67 
1 0.9% NaCl 1:3 73 
1 HES 130/0.4 1:9 87 
1 HES 130/0.4 1:9 66 
1 HES 130/0.4 1:3 82 
1 HES 130/0.4 1:3 77 
1 HES 200/0.5 1:9 84 
1 HES 200/0.5 1:9 96 
1 HES 200/0.5 1:3 95 
1 HES 200/0.5 1:3 92 
2 No dilution 73 
2 No dilution 75 
2 0.9% NaCl 1:9 97 
2 0.9% NaCl 1:9 74 
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2 0.9% NaCl 1:3 102 
2 0.9% NaCl 1:3 154* 
2 0.9% NaCl 1:3 88 
2 HES 130/0.4 1:9 86 
2 HES 130/0.4 1:9 88 
2 HES 130/0.4 1:3 160* 
2 HES 130/0.4 1:3 >300* 
2 HES 130/0.4 1:3 111 
2 HES 130/0.4 1:3 94 
2 HES 200/0.5 1:9 99* 
2 HES 200/0.5 1:9 71 
2 HES 200/0.5 1:9 77 
2 HES 200/0.5 1:3 129 
2 HES 200/0.5 1:3 131 
3 No dilution 72 
3 No dilution 71 
3 0.9% NaCl 1:9 62 
3 0.9% NaCl 1:9 62 
3 0.9% NaCl 1:3 104 
3 0.9% NaCl 1:3 74* 
3 0.9% NaCl 1:3 94 
3 HES 130/0.4 1:9 62 
3 HES 130/0.4 1:9 72 
3 HES 130/0.4 1:3 93 
3 HES 130/0.4 1:3 90 
3 HES 200/0.5 1:9 81 
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3 HES 200/0.5 1:9 72 
3 HES 200/0.5 1:3 141 
3 HES 200/0.5 1:3 99* 
3 HES 200/0.5 1:3 121 
4 No dilution 69 
4 No dilution 65 
4 0.9% NaCl 1:9 119* 
4 0.9% NaCl 1:9 108* 
4 0.9% NaCl 1:3 83 
4 0.9% NaCl 1:3 97 
4 HES 130/0.4 1:9 126 
4 HES 130/0.4 1:9 88* 
4 HES 130/0.4 1:9 125 
4 HES 130/0.4 1:3 184 
4 HES 130/0.4 1:3 205 
4 HES 200/0.5 1:9 84 
4 HES 200/0.5 1:9 93 
4 HES 200/0.5 1:3 >300* 
4 HES 200/0.5 1:3 180* 
4 HES 200/0.5 1:3 139 
4 HES 200/0.5 1:3 94* 
4 HES 200/0.5 1:3 140 
5 No dilution 71 
5 No dilution 66 
5 0.9% NaCl 1:9 87 
5 0.9% NaCl 1:9 72 
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5 0.9% NaCl 1:3 96 
5 0.9% NaCl 1:3 88 
5 HES 130/0.4 1:9 83 
5 HES 130/0.4 1:9 84 
5 HES 130/0.4 1:3 107 
5 HES 130/0.4 1:3 96 
5 HES 200/0.5 1:9 114 
5 HES 200/0.5 1:9 30 
5 HES 200/0.5 1:3 145 
5 HES 200/0.5 1:3 123 
6 No dilution 71 
6 No dilution 58 
6 0.9% NaCl 1:9 83 
6 0.9% NaCl 1:9 76 
6 0.9% NaCl 1:3 86 
6 0.9% NaCl 1:3 96 
6 HES 130/0.4 1:9 106 
6 HES 130/0.4 1:9 71* 
6 HES 130/0.4 1:9 93 
6 HES 130/0.4 1:3 155 
6 HES 130/0.4 1:3 123 
6 HES 200/0.5 1:9 96 
6 HES 200/0.5 1:9 84 
6 HES 200/0.5 1:3 116 
6 HES 200/0.5 1:3 100 
7 No dilution 77 
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7 No dilution 66 
7 0.9% NaCl 1:9 73 
7 0.9% NaCl 1:9 89 
7 0.9% NaCl 1:3 107 
7 0.9% NaCl 1:3 83 
7 HES 130/0.4 1:9 74 
7 HES 130/0.4 1:9 70 
7 HES 130/0.4 1:3 101 
7 HES 130/0.4 1:3 96 
7 HES 200/0.5 1:9 99* 
7 HES 200/0.5 1:9 71 
7 HES 200/0.5 1:9 80 
7 HES 200/0.5 1:3 198 
7 HES 200/0.5 1:3 100* 
7 HES 200/0.5 1:3 154 
8 No dilution 73 
8 No dilution 67 
8 0.9% NaCl 1:9 69 
8 0.9% NaCl 1:9 70 
8 0.9% NaCl 1:3 90 
8 0.9% NaCl 1:3 94 
8 HES 130/0.4 1:9 73 
8 HES 130/0.4 1:9 87 
8 HES 130/0.4 1:3 105 
8 HES 130/0.4 1:3 103 
8 HES 200/0.5 1:9 71 
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8 HES 200/0.5 1:9 76 
8 HES 200/0.5 1:3 120 
8 HES 200/0.5 1:3 116 
9 No dilution 87 
9 No dilution 66 
9 0.9% NaCl 1:9 68 
9 0.9% NaCl 1:9 89 
9 0.9% NaCl 1:3 115 
9 0.9% NaCl 1:3 84 
9 HES 130/0.4 1:9 109 
9 HES 130/0.4 1:9 79 
9 HES 130/0.4 1:3 112 
9 HES 130/0.4 1:3 86 
9 HES 200/0.5 1:9 84 
9 HES 200/0.5 1:9 81 
9 HES 200/0.5 1:3 127 
9 HES 200/0.5 1:3 121 
10 No dilution 86* 
10 No dilution 59 
10 No dilution 59 
10 0.9% NaCl 1:9 95* 
10 0.9% NaCl 1:9 65 
10 0.9% NaCl 1:9 62 
10 0.9% NaCl 1:3 107 
10 0.9% NaCl 1:3 86 
10 HES 130/0.4 1:9 122* 
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10 HES 130/0.4 1:9 70 
10 HES 130/0.4 1:9 68 
10 HES 130/0.4 1:3 147* 
10 HES 130/0.4 1:3 100 
10 HES 130/0.4 1:3 99 
10 HES 200/0.5 1:9 77 
10 HES 200/0.5 1:9 74 
10 HES 200/0.5 1:3 119 
10 HES 200/0.5 1:3 137 
Platelet closure time (PCT), sodium chloride (NaCl), hydroxyethyl starch (HES). 
*PCT excluded from statistical analysis. 
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Appendix B: Chapter 3 raw data – packed cell volumes and platelet counts  
Packed cell volume (PCV) and platelet count of each dog, and respective measurements with one in 
nine (1:9) and one in three (1:3) in vitro dilutions with 0.9% sodium chloride (NaCl). 
Dog PCV of dog 
(%) 
PCV of 1:9 
dilution 
with 0.9% 
NaCl (%) 
PCV of 1:3 
dilution 
with 0.9% 
NaCl (%) 
Platelet 
count of dog                         
(x 109 cells/L) 
Platelet 
count of 1:9 
dilution with 
0.9% NaCl   
(x 109 cells/L) 
Platelet 
count of 1:3 
dilution with 
0.9% NaCl    
(x 109 cells/L) 
1 54 50 42 259 288 326 
2 42 37 32 291 100 86 
3 48 42 37 292 270 172 
4 40 30 30 440 201 173 
5 52 41 35 192 240 191 
6 48 41 36 260 240 209 
7 42 40 33 250 246 216 
8 46 40 38 312 283 224 
9 50 46 38 216 270 225 
10 48 44 36 319 288 241 
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Appendix C: Chapter 4 raw data – closure times 
Closure times (CT) in greyhounds under general anaesthesia (T0), in haemorrhagic shock (T1), and 40 
minutes after receiving either 80ml/kg of 0.9% sodium chloride (NaCl) or 20ml/kg of hydroxyethyl 
starch (HES) 130/0.4  over 20 minutes (T2).  
Dog Solution PCT T0 PCT T1 PCT T2 
50811 0.9% NaCl 69 61 71 
  87 73 94 
90911  72 77 107 
  75 69 98 
A141011  67 62 72 
  70 64 100 
B141011  148 65 117 
  175 64 116 
  95*  73* 
A211011  67 50 88 
  80 62 92 
170611 HES 130/0.4 73 70 Flow obstruction# 
  60 68 Flow obstruction# 
80711  85 60 No closure# 
  78 67 No closure# 
260811  109 88 83 
  108 76 91 
    158* 
230911  81 72 83 
96 
 
  87 72 84 
A071011  90 116 122 
  79 90 102 
B071011  91 65 91 
  79 58 75 
* Data excluded from analysis 
# Data excluded from analysis due to platelet clumping in sample 
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Appendix D: Chapter 4 raw data - packed cell volume and platelet counts  
Packed cell volume and platelet counts of greyhounds under general anaesthesia (T0), during 
haemorrhagic shock (T1), and 40 minutes after received 0.9% sodium chloride (NaCl) or hydroxyethyl 
starch (HES) 130/0.4  .  
Dog Solution PCV 
(%) 
T0 
PCV 
(%) 
T1 
PCV 
(%) 
T2 
Platelet 
count  
(x 109 cells/L) 
T0 
 
Platelet 
count  
(x 109 cells/L) 
T1 
 
Platelet  
count  
(x 109 cells/L) 
T2 
 
50811 0.9% NaCl 54 51 34 179 156 107 
90911  47 50 30 169 149 122 
A141011  47 45 30 184 164 144 
B141011  47 46 33 190 178 133 
A211011  47 46 26 201 200 134 
170611 HES 130/0.4 50 47 N/A 136 118 N/A 
80711  54 48 N/A 174 140 N/A 
260811  48 43 29 151 110 38 
230911  50 47 29 184 166 86 
A071011  48 48 28 141 121 60 
B071011  50 45 31 186 143 94 
N/A Data not available 
 
 
